PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16098614-3	2005	We show that oral administration of the selective PPARdelta agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide.	GW0742	68-74	peroxisome proliferator activator receptor delta	Mus musculus	50-59
16098614-3	2005	We show that oral administration of the selective PPARdelta agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide.	GW0742	68-74	myelin oligodendrocyte glycoprotein	Mus musculus	163-198
16098614-3	2005	We show that oral administration of the selective PPARdelta agonist GW0742 reduced clinical symptoms in C57BL/6 mice that had been immunized with encephalitogenic myelin oligodendrocyte glycoprotein (MOG) peptide.	GW0742	68-74	myelin oligodendrocyte glycoprotein	Mus musculus	200-203
16098614-6	2005	Treatment of T-cells with GW0742 either in vivo or in vitro did not reduce IFNgamma production; however GW0742 reduced astroglial and microglial inflammatory activation and IL-1beta levels in EAE brain.	GW0742	104-110	interleukin 1 beta	Mus musculus	173-181
15939051-0	2005	The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.	GW0742	22-29	peroxisome proliferator activator receptor delta	Mus musculus	4-13
15939051-0	2005	The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice.	GW0742	22-29	low density lipoprotein receptor	Mus musculus	57-61
15939051-4	2005	We demonstrate here that the PPARdelta agonist, GW0742X has potent anti-atherogenic activity in the LDLR(-/-) mouse, decreasing lesion area by up to 50%.	GW0742	48-55	peroxisome proliferator activator receptor delta	Mus musculus	29-38
15939051-4	2005	We demonstrate here that the PPARdelta agonist, GW0742X has potent anti-atherogenic activity in the LDLR(-/-) mouse, decreasing lesion area by up to 50%.	GW0742	48-55	low density lipoprotein receptor	Mus musculus	100-104
15939051-6	2005	Treatment with GW0742X resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and intracellular adhesion moleculae 1 (ICAM-1) in the aortae of treated mice.	GW0742	15-22	chemokine (C-C motif) ligand 2	Mus musculus	59-93
15939051-6	2005	Treatment with GW0742X resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and intracellular adhesion moleculae 1 (ICAM-1) in the aortae of treated mice.	GW0742	15-22	chemokine (C-C motif) ligand 2	Mus musculus	95-100
15939051-6	2005	Treatment with GW0742X resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and intracellular adhesion moleculae 1 (ICAM-1) in the aortae of treated mice.	GW0742	15-22	intercellular adhesion molecule 1	Mus musculus	106-140
15939051-6	2005	Treatment with GW0742X resulted in decreased expression of monocyte chemoattractant protein 1 (MCP-1) and intracellular adhesion moleculae 1 (ICAM-1) in the aortae of treated mice.	GW0742	15-22	intercellular adhesion molecule 1	Mus musculus	142-148
33034416-0	2020	GW0742 activates miR-17-5p and inhibits TXNIP/NLRP3-mediated inflammation after hypoxic-ischaemic injury in rats and in PC12 cells.	GW0742	0-6	thioredoxin interacting protein	Rattus norvegicus	40-45
15211590-2	2004	We sought to examine the role of PPARbeta in neuronal cell death by using the PPARbeta ligand GW0742.	GW0742	94-100	peroxisome proliferator-activated receptor delta	Rattus norvegicus	78-86
15211590-6	2004	After 24 hr of exposure, PPARbeta activation by GW0742 was not inherently toxic to cerebellar granule neurons.	GW0742	48-54	peroxisome proliferator-activated receptor delta	Rattus norvegicus	25-33
12699745-3	2003	Optimization of these hits by structure-guided design led to 7k (GW501516) and 7l (GW0742), which shows an EC(50) of 1.1 nM against PPARdelta with 1000-fold selectivity over the other human subtypes.	GW0742	83-89	peroxisome proliferator activated receptor delta	Homo sapiens	132-141
15793256-4	2005	Specific activation of PPARdelta using two pharmacological agonists (GW501516 and GW0742) increased glucose uptake independently of insulin in differentiated C2C12 myotubes.	GW0742	82-88	peroxisome proliferator activated receptor delta	Homo sapiens	23-32
14684157-6	2004	Palmitate oxidation rates were significantly increased in both neonatal and adult cardiomyocytes after treatment of a PPARdelta-selective ligand (GW0742).	GW0742	146-152	peroxisome proliferator activator receptor delta	Mus musculus	118-127
14684157-9	2004	GW0742 can restore partly the expression of certain key genes of fatty acid oxidation in mouse adult cardiomyocytes isolated from PPARalpha knockout mice.	GW0742	0-6	peroxisome proliferator activated receptor alpha	Mus musculus	130-139
33034416-0	2020	GW0742 activates miR-17-5p and inhibits TXNIP/NLRP3-mediated inflammation after hypoxic-ischaemic injury in rats and in PC12 cells.	GW0742	0-6	NLR family, pyrin domain containing 3	Rattus norvegicus	46-51
33034416-8	2020	Mechanistically, GW0742 significantly decreased the expression of TXNIP, NLRP3, IL-6 and TNF-alpha.	GW0742	17-23	thioredoxin interacting protein	Rattus norvegicus	66-71
33034416-8	2020	Mechanistically, GW0742 significantly decreased the expression of TXNIP, NLRP3, IL-6 and TNF-alpha.	GW0742	17-23	NLR family, pyrin domain containing 3	Rattus norvegicus	73-78
33034416-8	2020	Mechanistically, GW0742 significantly decreased the expression of TXNIP, NLRP3, IL-6 and TNF-alpha.	GW0742	17-23	interleukin 6	Rattus norvegicus	80-84
33034416-8	2020	Mechanistically, GW0742 significantly decreased the expression of TXNIP, NLRP3, IL-6 and TNF-alpha.	GW0742	17-23	tumor necrosis factor	Rattus norvegicus	89-98
33034416-9	2020	Either PPAR-beta/delta antagonist GSK3787, miR-17-5p inhibitor, or TXNIP CRISPR activation abolished the anti-inflammatory effects of GW0742.	GW0742	134-140	peroxisome proliferator activated receptor alpha	Rattus norvegicus	7-22
33034416-9	2020	Either PPAR-beta/delta antagonist GSK3787, miR-17-5p inhibitor, or TXNIP CRISPR activation abolished the anti-inflammatory effects of GW0742.	GW0742	134-140	thioredoxin interacting protein	Rattus norvegicus	67-72
33034416-10	2020	Activation of PPAR-beta/delta by GW0742 activated miR-17-5p expression in PC12 cells and increased cell viability after OGD, which was accompanied by decreased expression of TXNIP and reduced secretion of IL-1beta and TNF-alpha.	GW0742	33-39	peroxisome proliferator activated receptor alpha	Rattus norvegicus	14-23
33034416-10	2020	Activation of PPAR-beta/delta by GW0742 activated miR-17-5p expression in PC12 cells and increased cell viability after OGD, which was accompanied by decreased expression of TXNIP and reduced secretion of IL-1beta and TNF-alpha.	GW0742	33-39	thioredoxin interacting protein	Rattus norvegicus	174-179
33034416-10	2020	Activation of PPAR-beta/delta by GW0742 activated miR-17-5p expression in PC12 cells and increased cell viability after OGD, which was accompanied by decreased expression of TXNIP and reduced secretion of IL-1beta and TNF-alpha.	GW0742	33-39	interleukin 1 alpha	Rattus norvegicus	205-213
33034416-10	2020	Activation of PPAR-beta/delta by GW0742 activated miR-17-5p expression in PC12 cells and increased cell viability after OGD, which was accompanied by decreased expression of TXNIP and reduced secretion of IL-1beta and TNF-alpha.	GW0742	33-39	tumor necrosis factor	Rattus norvegicus	218-227
23056034-1	2012	The aim of this study is to investigate the neuroprotective effects and relevant mechanism of GW0742, an agonist of PPAR-beta, after global cerebral ischemia-reperfusion injury (GCIRI) in rats.	GW0742	94-100	peroxisome proliferator-activated receptor delta	Rattus norvegicus	116-125
23056034-5	2012	Similarly, GW0742 pretreatment also improved the GCIRI-induced decrease in the expression of IL-10, which can act as an inhibitory cytokine to reduce cerebral ischemic injury.	GW0742	11-17	interleukin 10	Rattus norvegicus	93-98
23056034-6	2012	For another, NF-kappaB p65 expression was significantly increased in hippocampal neurons with apparent nuclear translocation after global cerebral IRI, and these phenomena were also largely attenuated by GW0742 pretreatment.	GW0742	204-210	synaptotagmin 1	Rattus norvegicus	23-26
23056034-8	2012	Our data suggests that the PPAR-beta agonist GW0742 can exert significant neuroprotective effect against GCIRI in rats via PPAR-beta activation and its anti-inflammation effect mediated by the inhibition of expression and activation of NF-kappaB in the hippocampus.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-36
23056034-8	2012	Our data suggests that the PPAR-beta agonist GW0742 can exert significant neuroprotective effect against GCIRI in rats via PPAR-beta activation and its anti-inflammation effect mediated by the inhibition of expression and activation of NF-kappaB in the hippocampus.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	123-132
34699845-7	2022	The effect of high glucose was inhibited by GW0742, a PPARbeta agonist.	GW0742	44-50	peroxisome proliferator activated receptor alpha	Rattus norvegicus	54-62
34387896-11	2022	Accordingly, pretreatment of LPS treated HepG2 cells with the PPARdelta agonist GW0742, suppressed mRNA expression of inflammatory markers.	GW0742	80-86	peroxisome proliferator activated receptor delta	Homo sapiens	62-71
34699845-8	2022	Both GSK0660 (PPARbeta antagonist) and NG-nitro-l-arginine-methyl ester (NOS inhibitor) could reverse the protective effects of GW0742.	GW0742	128-134	peroxisome proliferator activated receptor alpha	Rattus norvegicus	14-22
34102191-10	2021	VDR-silencing or GW0742-mediated blockade of VDR activity can partially reverse the JAK2 inhibition resistance.	GW0742	17-23	vitamin D receptor	Homo sapiens	45-48
34102191-10	2021	VDR-silencing or GW0742-mediated blockade of VDR activity can partially reverse the JAK2 inhibition resistance.	GW0742	17-23	Janus kinase 2	Homo sapiens	84-88
33646450-11	2021	CONCLUSION: Our results indicate that GW0742 may serve as a candidate agent to mitigate cisplatin nephrotoxicity via inhibiting the mitochondrial apoptotic pathway considerably depending on PPAR-delta, without modulating autophagy.	GW0742	38-44	peroxisome proliferator activator receptor delta	Mus musculus	190-200
34203800-3	2021	For this purpose, rats were treated with PPARbeta/delta agonist GW0742 and/or antagonist GSK0660 in vivo and hearts were subjected to ex vivo global ischemia followed by reperfusion.	GW0742	64-70	peroxisome proliferator activated receptor alpha	Rattus norvegicus	41-49
35461240-7	2022	Through specific DNA fragmentation quantification and qRT-PCR experiments, we evidenced in vitro an increased resistance to oxidative stress in MSC pre-treated by the PPARbeta/delta agonist GW0742 versus naive MSC.	GW0742	190-196	peroxisome proliferator activated receptor alpha	Mus musculus	167-181
33646450-7	2021	RESULTS: GW0742 suppressed cisplatin-induced apoptosis of mProx cells by reducing the activation of caspase-3 via attenuating the phosphorylation of p53 and 14-3-3, mitochondrial Bax accumulation, cytochrome C release from mitochondria to the cytosol and ensuing cytosolic caspase-9 activation.	GW0742	9-15	caspase 3	Mus musculus	100-109
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	peroxisome proliferator activated receptor alpha	Mus musculus	14-28
33646450-7	2021	RESULTS: GW0742 suppressed cisplatin-induced apoptosis of mProx cells by reducing the activation of caspase-3 via attenuating the phosphorylation of p53 and 14-3-3, mitochondrial Bax accumulation, cytochrome C release from mitochondria to the cytosol and ensuing cytosolic caspase-9 activation.	GW0742	9-15	transformation related protein 53, pseudogene	Mus musculus	149-163
33646450-7	2021	RESULTS: GW0742 suppressed cisplatin-induced apoptosis of mProx cells by reducing the activation of caspase-3 via attenuating the phosphorylation of p53 and 14-3-3, mitochondrial Bax accumulation, cytochrome C release from mitochondria to the cytosol and ensuing cytosolic caspase-9 activation.	GW0742	9-15	BCL2-associated X protein	Mus musculus	179-182
33646450-7	2021	RESULTS: GW0742 suppressed cisplatin-induced apoptosis of mProx cells by reducing the activation of caspase-3 via attenuating the phosphorylation of p53 and 14-3-3, mitochondrial Bax accumulation, cytochrome C release from mitochondria to the cytosol and ensuing cytosolic caspase-9 activation.	GW0742	9-15	caspase 9	Mus musculus	273-282
33646450-9	2021	The inhibitory effect of GW0742 on cisplatin-induced caspase-3 activation was significantly diminished by silencing of the PPAR-delta gene expression.	GW0742	25-31	caspase 3	Mus musculus	53-62
33646450-9	2021	The inhibitory effect of GW0742 on cisplatin-induced caspase-3 activation was significantly diminished by silencing of the PPAR-delta gene expression.	GW0742	25-31	peroxisome proliferator activator receptor delta	Mus musculus	123-133
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	interleukin 6	Mus musculus	115-118
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	interleukin 1 alpha	Mus musculus	120-127
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	tumor necrosis factor	Mus musculus	129-137
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	matrix metallopeptidase 13	Mus musculus	139-143
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	matrix metallopeptidase 2	Mus musculus	149-153
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	interleukin 6	Mus musculus	175-178
33790957-6	2021	The selective PPARbeta/delta agonist GW0742 significantly decreased inflammation-related mRNA expression in hDPCs (IL6, IL1beta, TNFalpha, MMP1, and MMP2) and RAW264.7 cells (Il6 and Tnfalpha).	GW0742	37-43	tumor necrosis factor	Mus musculus	183-191
33790957-11	2021	In addition, they suggest that activation of PPARbeta/delta by GW0742 can attenuate some cellular and molecular in vitro aspects related to the inflammatory process, pointing out to investigate its potential target role in dental pulp inflammation.	GW0742	63-69	peroxisome proliferator activated receptor alpha	Homo sapiens	45-53
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	insulin like growth factor binding protein 1	Homo sapiens	116-123
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	interleukin 11	Homo sapiens	125-130
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	vascular endothelial growth factor A	Homo sapiens	135-139
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	estrogen receptor 1	Homo sapiens	183-190
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	S100 calcium binding protein A6	Homo sapiens	192-203
32594141-9	2020	GW0742 treatment enhanced hormone-mediated ESC decidualization in vitro as manifested by upregulation of prolactin, IGFBP-1, IL-11 and VEGF secretion and also increased expression of ERalpha, PR-A and -B and Cx43.	GW0742	0-6	gap junction protein alpha 1	Homo sapiens	208-212
32398728-0	2020	Context-dependent regulation of endothelial cell metabolism: differential effects of the PPARbeta/delta agonist GW0742 and VEGF-A.	GW0742	112-118	peroxisome proliferator activated receptor alpha	Homo sapiens	89-97
32037375-6	2020	PPARD expression in the luteal tissue was stimulated (P < 0.05) by GW0742, known as a selective PPARD agonist, and PPARD ligands (i.e., arachidonic, linoleic and linolenic acids).	GW0742	70-76	peroxisome proliferator activated receptor delta	Bos taurus	0-5
32037375-6	2020	PPARD expression in the luteal tissue was stimulated (P < 0.05) by GW0742, known as a selective PPARD agonist, and PPARD ligands (i.e., arachidonic, linoleic and linolenic acids).	GW0742	70-76	peroxisome proliferator activated receptor delta	Bos taurus	99-104
32037375-6	2020	PPARD expression in the luteal tissue was stimulated (P < 0.05) by GW0742, known as a selective PPARD agonist, and PPARD ligands (i.e., arachidonic, linoleic and linolenic acids).	GW0742	70-76	peroxisome proliferator activated receptor delta	Bos taurus	99-104
33426208-2	2020	Previous study has reported that mixture of GW0742 (PPAR-delta agonist), hyaluronic acid (HA) and mesenchymal stem cells (MSCs) enhance chondrogenesis.	GW0742	44-50	peroxisome proliferator activated receptor delta	Homo sapiens	52-62
33426208-11	2020	GW0742 decreased the expression of PPAR-gamma with/without inflammation condition.	GW0742	0-6	peroxisome proliferator activated receptor gamma	Homo sapiens	35-45
32398728-2	2020	This study characterised the metabolic response of HUVEC to the PPARbeta/delta agonist, GW0742, and compared these effects with those induced by VEGF-A.	GW0742	88-94	peroxisome proliferator activated receptor alpha	Homo sapiens	64-78
31008686-6	2019	In this study, the effects of GW0742 (a selective PPAR-delta agonist) on hippocampal synaptic transmission, plasticity, and spatial memory were investigated in the db/db mouse model of T2DM.	GW0742	30-36	peroxisome proliferator activator receptor delta	Mus musculus	50-60
31939088-3	2020	The present study was undertaken to evaluate the protective effects of PPAR-beta/delta activation using a selective PPAR-beta/delta agonist, GW0742, against brain injury after ICH in a mouse model.	GW0742	141-147	peroxisome proliferator activated receptor alpha	Mus musculus	71-80
31939088-3	2020	The present study was undertaken to evaluate the protective effects of PPAR-beta/delta activation using a selective PPAR-beta/delta agonist, GW0742, against brain injury after ICH in a mouse model.	GW0742	141-147	peroxisome proliferator activated receptor alpha	Mus musculus	116-125
31939088-10	2020	Mice treated with GW0742 showed significantly less severe behavioral deficits compared to the control group, accompanied by increased expression of PPAR-beta/delta and Bcl-2, and increased expression of IL-1beta, TNF-alpha, and Bax decreased simultaneously in the GW0742-treated group.	GW0742	18-24	peroxisome proliferator activated receptor alpha	Mus musculus	148-163
31939088-10	2020	Mice treated with GW0742 showed significantly less severe behavioral deficits compared to the control group, accompanied by increased expression of PPAR-beta/delta and Bcl-2, and increased expression of IL-1beta, TNF-alpha, and Bax decreased simultaneously in the GW0742-treated group.	GW0742	18-24	B cell leukemia/lymphoma 2	Mus musculus	168-173
31939088-10	2020	Mice treated with GW0742 showed significantly less severe behavioral deficits compared to the control group, accompanied by increased expression of PPAR-beta/delta and Bcl-2, and increased expression of IL-1beta, TNF-alpha, and Bax decreased simultaneously in the GW0742-treated group.	GW0742	18-24	interleukin 1 alpha	Mus musculus	203-211
31939088-10	2020	Mice treated with GW0742 showed significantly less severe behavioral deficits compared to the control group, accompanied by increased expression of PPAR-beta/delta and Bcl-2, and increased expression of IL-1beta, TNF-alpha, and Bax decreased simultaneously in the GW0742-treated group.	GW0742	18-24	tumor necrosis factor	Mus musculus	213-222
31939088-10	2020	Mice treated with GW0742 showed significantly less severe behavioral deficits compared to the control group, accompanied by increased expression of PPAR-beta/delta and Bcl-2, and increased expression of IL-1beta, TNF-alpha, and Bax decreased simultaneously in the GW0742-treated group.	GW0742	18-24	BCL2-associated X protein	Mus musculus	228-231
31635041-5	2019	24 mice were assigned to groups according to an 8-week exercise training program and/or an 8-week treatment with 3 mg/kg/day of GW0742, a PPARbeta/delta agonist.	GW0742	128-134	peroxisome proliferator activator receptor delta	Mus musculus	138-146
30453390-0	2019	PPARbeta/delta-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1DeltaE9 astrocytes.	GW0742	23-29	peroxisome proliferator activator receptor delta	Mus musculus	0-8
30453390-5	2019	The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism.	GW0742	133-139	peroxisome proliferator activator receptor delta	Mus musculus	59-107
30453390-5	2019	The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARbeta/delta) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism.	GW0742	133-139	peroxisome proliferator activator receptor delta	Mus musculus	109-117
30453390-6	2019	GW0742 enhanced the expression of CPT1a, the gene encoding for a rate-limiting enzyme of fatty acid oxidation.	GW0742	0-6	carnitine palmitoyltransferase 1a, liver	Mus musculus	34-39
30453390-7	2019	Similarly, treatment of a mouse model of AD, the APP/PS1-mice, with GW0742 increased the expression of Cpt1a and concomitantly reversed memory deficits in a fear conditioning test.	GW0742	68-74	presenilin 1	Mus musculus	53-56
30453390-7	2019	Similarly, treatment of a mouse model of AD, the APP/PS1-mice, with GW0742 increased the expression of Cpt1a and concomitantly reversed memory deficits in a fear conditioning test.	GW0742	68-74	carnitine palmitoyltransferase 1a, liver	Mus musculus	103-108
30129179-0	2018	GW0742 activates peroxisome proliferator-activated receptor delta to reduce free radicals and alleviate cardiac hypertrophy induced by hyperglycemia in cultured H9c2 cells.	GW0742	0-6	peroxisome proliferator-activated receptor delta	Rattus norvegicus	17-65
30129179-3	2018	Then, H9c2 cells incubated with high glucose to induce hypertrophy were used to investigate using GW0742 to activate PPARdelta.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	117-126
30129179-9	2018	These effects of GW0742 were dose-dependently inhibited by GSK0660 indicating an activation of PPARdelta by GW0742 to alleviate cardiac hypertrophy.	GW0742	17-23	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-104
30129179-9	2018	These effects of GW0742 were dose-dependently inhibited by GSK0660 indicating an activation of PPARdelta by GW0742 to alleviate cardiac hypertrophy.	GW0742	108-114	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-104
30129179-11	2018	GW0742 promoted the expression of thioredoxin, an antioxidant enzyme.	GW0742	0-6	thioredoxin 1	Rattus norvegicus	34-45
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-52
30227151-0	2018	The PPARdelta agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model.	GW0742	22-28	peroxisome proliferator activator receptor delta	Mus musculus	4-13
30227151-0	2018	The PPARdelta agonist GW0742 restores neuroimmune function by regulating Tim-3 and Th17/Treg-related signaling in the BTBR autistic mouse model.	GW0742	22-28	hepatitis A virus cellular receptor 2	Mus musculus	73-78
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	interleukin 17A	Mus musculus	65-71
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	signal transducer and activator of transcription 3	Mus musculus	84-89
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	hepatitis A virus cellular receptor 2	Mus musculus	91-96
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	interferon gamma	Mus musculus	102-111
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	interleukin 10	Mus musculus	166-171
30227151-9	2018	GW0742 attenuated the expression of inflammatory markers such as IL-17A, RORgammaT, Stat3, TIM-3, and IFN-gamma, while upregulating anti-inflammatory markers such as IL-10/Foxp3 both in the brain and periphery of BTBR mice.	GW0742	0-6	forkhead box P3	Mus musculus	172-177
29580823-0	2018	GW0742 (PPAR-beta agonist) attenuates hepatic endoplasmic reticulum stress by improving hepatic energy metabolism in high-fat diet fed mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	8-17
29580823-3	2018	This study aimed to investigate the effects of GW0742 (PPAR-beta agonist) on hepatic energy metabolism and ER stress in a murine diet-induced obesity model.	GW0742	47-53	peroxisome proliferator activator receptor delta	Mus musculus	55-64
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	microRNA 17	Rattus norvegicus	87-93
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	thioredoxin interacting protein	Rattus norvegicus	122-127
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	mitogen-activated protein kinase kinase kinase 5	Rattus norvegicus	132-136
30086290-3	2018	In the present study, we hypothesized that PPAR-beta/delta agonist GW0742 can activate miR-17-5p, consequently inhibiting TXNIP and ASK1/p38 pathway leading to attenuation of apoptosis.	GW0742	67-73	mitogen activated protein kinase 14	Rattus norvegicus	137-140
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	40-49
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	microRNA 17	Rattus norvegicus	79-85
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	thioredoxin interacting protein	Rattus norvegicus	107-112
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	mitogen-activated protein kinase kinase kinase 5	Rattus norvegicus	176-180
30086290-9	2018	Furthermore, GW0742 treatment increased PPAR-beta/delta nuclear expression and miR-17-5p level and reduced TXNIP in ipsilateral hemisphere after HI, resulting in inhibition of ASK1/p38 pathway and attenuation of apoptosis.	GW0742	13-19	mitogen activated protein kinase 14	Rattus norvegicus	181-184
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-83
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	peroxisome proliferator-activated receptor delta	Rattus norvegicus	156-165
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	microRNA 17	Rattus norvegicus	172-178
30086290-11	2018	For the first time, we provide evidence that intranasal administration of PPAR-beta/delta agonist GW0742 attenuated neuronal apoptosis at least in part via PPAR-beta/delta/miR-17/TXNIP pathway.	GW0742	98-104	thioredoxin interacting protein	Rattus norvegicus	179-184
29621036-6	2018	The known PPAR-delta agonists, GW1516, L165041, and GW0742, showed potent agonist activity against human, mouse, and rat receptors (ranging from 165- to 396-fold).	GW0742	52-58	peroxisome proliferator activated receptor delta	Homo sapiens	10-20
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	GW0742	206-212	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	128-133
30046379-3	2018	HUVECs exposed to high glucose showed increased levels of reactive oxygen species (ROS) and upregulated NOX-2, NOX-4, Nrf2, and NQO-1 effects that were significantly reversed by the PPARbeta/delta agonists GW0742 and L165041.	GW0742	206-212	peroxisome proliferator-activated receptor delta	Rattus norvegicus	182-190
29697010-2	2018	We hypothesized that the PPAR-beta/delta-agonist GW0742 improves long-term outcome after sepsis caused by cecal ligation and puncture (CLP).	GW0742	49-55	peroxisome proliferator activator receptor delta	Mus musculus	25-34
29697010-7	2018	Compared to vehicle, CLP mice treated with GW0742 exhibited a 50% reduction in the circulating plasminogen activator inhibitor-1 associated with an increase in platelet number at 24 h post-CLP (but no changes occurred in anti-thrombin-III, plasminogen, fibrinogen and clotting-times).	GW0742	43-49	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	95-128
28825467-1	2017	We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor delta (PPARdelta) agonist.	GW0742	55-61	peroxisome proliferator activated receptor delta	Homo sapiens	65-113
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-62	peroxisome proliferator-activated receptor delta	Capra hircus	28-33
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-62	peroxisome proliferator-activated receptor delta	Capra hircus	43-48
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-62	long-chain-fatty-acid--CoA ligase 1	Capra hircus	118-123
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-58	peroxisome proliferator-activated receptor delta	Capra hircus	28-33
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-58	peroxisome proliferator-activated receptor delta	Capra hircus	43-48
29331469-6	2018	The cultures overexpressing PPARD with the PPARD ligand GW0742 (GW) upregulated the expression of CD36, FABP3, FABP4, ACSL1, and ADRP.	GW0742	56-58	long-chain-fatty-acid--CoA ligase 1	Capra hircus	118-123
29331469-7	2018	Overexpression of PPARD in GMEC plus GW increased the concentration of 16:1 and 18:1-trans and was associated with upregulation of SCD1.	GW0742	37-39	stearoyl-CoA desaturase	Capra hircus	131-135
29287957-0	2018	Novel VDR antagonists based on the GW0742 scaffold.	GW0742	35-41	vitamin D receptor	Homo sapiens	6-9
29287957-5	2018	Herein, we report the rational design of non-secosteroid VDR antagonists using GW0742 as a scaffold.	GW0742	79-85	vitamin D receptor	Homo sapiens	57-60
29287957-6	2018	GW0742 is a PPARdelta agonist previously identified by our group as a VDR antagonist.	GW0742	0-6	peroxisome proliferator activated receptor delta	Homo sapiens	12-21
29287957-6	2018	GW0742 is a PPARdelta agonist previously identified by our group as a VDR antagonist.	GW0742	0-6	vitamin D receptor	Homo sapiens	70-73
28969938-8	2018	RESULTS: In mice treated with high-dose GW0742, plasma levels of IL-6, IL-1beta, and MCP-1 were significantly increased compared to the control group mice.	GW0742	40-46	interleukin 6	Mus musculus	65-69
28969938-8	2018	RESULTS: In mice treated with high-dose GW0742, plasma levels of IL-6, IL-1beta, and MCP-1 were significantly increased compared to the control group mice.	GW0742	40-46	interleukin 1 beta	Mus musculus	71-79
28969938-8	2018	RESULTS: In mice treated with high-dose GW0742, plasma levels of IL-6, IL-1beta, and MCP-1 were significantly increased compared to the control group mice.	GW0742	40-46	mast cell protease 1	Mus musculus	85-90
28969938-9	2018	When compared to mice treated with low-dose GW0742 plasma levels of IL-6, IL-1beta, GM-CSF, KC, and MCP-1 were significantly elevated in high-dose-treated mice.	GW0742	44-50	interleukin 6	Mus musculus	68-72
28969938-9	2018	When compared to mice treated with low-dose GW0742 plasma levels of IL-6, IL-1beta, GM-CSF, KC, and MCP-1 were significantly elevated in high-dose-treated mice.	GW0742	44-50	interleukin 1 beta	Mus musculus	74-82
28969938-9	2018	When compared to mice treated with low-dose GW0742 plasma levels of IL-6, IL-1beta, GM-CSF, KC, and MCP-1 were significantly elevated in high-dose-treated mice.	GW0742	44-50	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	84-90
28969938-9	2018	When compared to mice treated with low-dose GW0742 plasma levels of IL-6, IL-1beta, GM-CSF, KC, and MCP-1 were significantly elevated in high-dose-treated mice.	GW0742	44-50	mast cell protease 1	Mus musculus	100-105
28034288-2	2018	Studies have shown that GW0742 has off target, non- PPARbeta/delta effects in the cell although there are some key questions that remain to be addressed in respect to the significance of this control on vascular tone.	GW0742	24-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	52-60
28034288-4	2018	RESULTS: Our data shows that the PPARbeta/delta agonist GW0742 (10-7M) inhibits contractile responses to U46619 and phenylephrine, and that these responses are similar in normal and Streptozotocin (STZ) diabetic rat aorta.	GW0742	56-62	peroxisome proliferator-activated receptor delta	Rattus norvegicus	33-41
29208022-1	2017	BACKGROUND: We tested whether GW0742, a peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist, improves endothelial dysfunction induced by plasma from patients with systemic lupus erythematosus (SLE) involving the inhibition of endoplasmic reticulum (ER) stress.	GW0742	30-36	peroxisome proliferator activated receptor delta	Homo sapiens	40-93
29208022-1	2017	BACKGROUND: We tested whether GW0742, a peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist, improves endothelial dysfunction induced by plasma from patients with systemic lupus erythematosus (SLE) involving the inhibition of endoplasmic reticulum (ER) stress.	GW0742	30-36	peroxisome proliferator activated receptor delta	Homo sapiens	95-103
28825467-1	2017	We describe the parallel synthesis of novel analogs of GW0742, a peroxisome proliferator-activated receptor delta (PPARdelta) agonist.	GW0742	55-61	peroxisome proliferator activated receptor delta	Homo sapiens	115-124
28825467-5	2017	We identified many potent PPARdelta agonists that were less toxic than GW0742, where ~65 of the compounds synthesized exhibited partial PPARdelta activity (23-98%) with EC50 values ranging from 0.007-18.2 muM.	GW0742	71-77	peroxisome proliferator activated receptor delta	Homo sapiens	26-35
28825467-5	2017	We identified many potent PPARdelta agonists that were less toxic than GW0742, where ~65 of the compounds synthesized exhibited partial PPARdelta activity (23-98%) with EC50 values ranging from 0.007-18.2 muM.	GW0742	71-77	peroxisome proliferator activated receptor delta	Homo sapiens	136-145
28901183-9	2017	GW0742, a PPAR-delta agonist, greatly enhanced MSC chondrogenesis and the expression of type II collagen and glycosaminoglycan (GAG) in hBM-MSC-derived chondrocytes.	GW0742	0-6	peroxisome proliferator activated receptor delta	Homo sapiens	10-20
28901183-10	2017	GW0742 also increased the expression of transforming growth factor beta that enhances chondrogenesis and suppresses cartilage fibrillation, ossification, and inflammation.	GW0742	0-6	transforming growth factor beta 1	Homo sapiens	40-71
27939528-6	2017	We found that treatment of mice with GW0742 increased, at day 4 post-damage, the recruitment of immune cells (M1 and M2 macrophages) and upregulated the expression of the anti-inflammatory cytokine IL-10 and TGF-beta mRNA.	GW0742	37-43	interleukin 10	Mus musculus	198-203
27939528-6	2017	We found that treatment of mice with GW0742 increased, at day 4 post-damage, the recruitment of immune cells (M1 and M2 macrophages) and upregulated the expression of the anti-inflammatory cytokine IL-10 and TGF-beta mRNA.	GW0742	37-43	transforming growth factor, beta 1	Mus musculus	208-216
27939528-9	2017	Differential effects of GW0742 observed during the regeneration were associated with variations of PPARbeta pathway activity.	GW0742	24-30	peroxisome proliferator activator receptor delta	Mus musculus	99-107
27519769-10	2016	Interestingly, the increased expression of fibrosis-associated proteins, including signal transducer and activator of transcription 3 (STAT3) was attenuated by the co-incubation of GW0742, a PPARdelta agonist.	GW0742	181-187	signal transducer and activator of transcription 3	Rattus norvegicus	83-133
28242713-2	2017	We tested whether GW0742, a peroxisome proliferator activator receptor beta/delta (PPARbeta/delta) agonist, ameliorates disease activity and cardiovascular complications in a female mouse model of lupus.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	83-91
28242713-9	2017	All these effects of GW0742 were inhibited by PPARbeta/delta blockade with GSK0660.	GW0742	21-27	peroxisome proliferator activator receptor delta	Mus musculus	46-54
27818230-0	2017	Effect of PPAR-beta/delta agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury.	GW0742	34-40	peroxisome proliferator activator receptor delta	Mus musculus	10-19
27818230-5	2017	In the present study, we determined for the first time, the effects of GW0742, a PPAR-beta/delta agonist on the APR following brain injury and assessed the effects on BBB permeability and tight junction integrity via claudin-5, occludin, and zona occludens-1 expression.	GW0742	71-77	peroxisome proliferator activator receptor delta	Mus musculus	81-90
27519769-10	2016	Interestingly, the increased expression of fibrosis-associated proteins, including signal transducer and activator of transcription 3 (STAT3) was attenuated by the co-incubation of GW0742, a PPARdelta agonist.	GW0742	181-187	peroxisome proliferator-activated receptor delta	Rattus norvegicus	191-200
28327554-4	2017	Activation of PPARbeta/delta by GW0742 and adenoviruses PPARbeta/delta (Ad-PPARbeta/delta) significantly inhibited hemoglobin-induced VSMC phenotypic switch.	GW0742	32-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
27789312-6	2017	GW0742, a selective and high-affinity PPARbeta/delta agonist, attenuated the corticosterone-induced astrocyte damage, but also significantly reversed the increase in the expression of GRP78 and CHOP, the two predominant proteins in endoplasmic reticulum (ER) stress.	GW0742	0-6	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-46
27789312-6	2017	GW0742, a selective and high-affinity PPARbeta/delta agonist, attenuated the corticosterone-induced astrocyte damage, but also significantly reversed the increase in the expression of GRP78 and CHOP, the two predominant proteins in endoplasmic reticulum (ER) stress.	GW0742	0-6	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	184-189
27789312-6	2017	GW0742, a selective and high-affinity PPARbeta/delta agonist, attenuated the corticosterone-induced astrocyte damage, but also significantly reversed the increase in the expression of GRP78 and CHOP, the two predominant proteins in endoplasmic reticulum (ER) stress.	GW0742	0-6	DNA-damage inducible transcript 3	Rattus norvegicus	194-198
27789312-7	2017	Moreover, GW0742 decreased the levels of caspase-12 and cleaved caspase-3, thereby protecting astrocytes against corticosterone-induced astrocyte apoptosis.	GW0742	10-16	caspase 12	Rattus norvegicus	41-51
27789312-9	2017	Finally, we demonstrated that PPARbeta/delta activation by GW0742 noticeably inhibited the activities and expression of DNA methyltransferases, and reduced the corticosterone-induced CpG island hypermethylation of microRNA-181a1 in astrocytes.	GW0742	59-65	peroxisome proliferator-activated receptor delta	Rattus norvegicus	30-38
27413020-3	2016	Herein, we aimed to analyse the possible protective effects of the PPARbeta/delta agonist GW0742 on the hyperglycaemic-induced impairment of cAMP-induced relaxation and Kv channel function in rat CA.	GW0742	90-96	peroxisome proliferator-activated receptor delta	Rattus norvegicus	67-75
27413020-5	2016	The protective effect of GW0742 was supressed by a PPARbeta/delta antagonist.	GW0742	25-31	peroxisome proliferator-activated receptor delta	Rattus norvegicus	51-59
27413020-12	2016	Finally, the preventive effect of GW0742 on oxidative stress and cAMP-induced relaxation were overcome by the pyruvate dehydrogenase kinase 4 (PDK4) inhibitor dichloroacetate (DCA).	GW0742	34-40	pyruvate dehydrogenase kinase 4	Rattus norvegicus	110-141
27413020-12	2016	Finally, the preventive effect of GW0742 on oxidative stress and cAMP-induced relaxation were overcome by the pyruvate dehydrogenase kinase 4 (PDK4) inhibitor dichloroacetate (DCA).	GW0742	34-40	pyruvate dehydrogenase kinase 4	Rattus norvegicus	143-147
27413020-13	2016	Our results reveal that the PPARbeta/delta agonist GW0742 prevents the impairment of the cAMP-mediated relaxation in CA under HG.	GW0742	51-57	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-36
27519769-10	2016	Interestingly, the increased expression of fibrosis-associated proteins, including signal transducer and activator of transcription 3 (STAT3) was attenuated by the co-incubation of GW0742, a PPARdelta agonist.	GW0742	181-187	signal transducer and activator of transcription 3	Rattus norvegicus	135-140
26655383-2	2016	Molecular mechanisms were investigated using differentiated C2C12 myotubes treated with alpha-LA and/or PPARbeta agonist GW0742.	GW0742	121-127	peroxisome proliferator activator receptor delta	Mus musculus	104-112
27189971-4	2016	GW0742 prevented the increase in both arterial blood pressure and plasma noradrenaline levels and the higher reduction of blood pressure after ganglionic blockade, whereas it reduced the mesenteric arterial remodeling and the hyper-responsiveness to vasoconstrictors (AngII and endothelin-1) in AngII-infused mice.	GW0742	0-6	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	268-273
27189971-4	2016	GW0742 prevented the increase in both arterial blood pressure and plasma noradrenaline levels and the higher reduction of blood pressure after ganglionic blockade, whereas it reduced the mesenteric arterial remodeling and the hyper-responsiveness to vasoconstrictors (AngII and endothelin-1) in AngII-infused mice.	GW0742	0-6	endothelin 1	Mus musculus	278-290
27189971-4	2016	GW0742 prevented the increase in both arterial blood pressure and plasma noradrenaline levels and the higher reduction of blood pressure after ganglionic blockade, whereas it reduced the mesenteric arterial remodeling and the hyper-responsiveness to vasoconstrictors (AngII and endothelin-1) in AngII-infused mice.	GW0742	0-6	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	295-300
27189971-8	2016	Small interfering RNA targeting RGS5 caused augmented contractile response to AngII in resistance mesenteric arteries and blunted the inhibitory effect of GW0742 on this response.	GW0742	155-161	regulator of G-protein signaling 5	Mus musculus	32-36
27189971-9	2016	In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation.	GW0742	15-21	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	122-127
27189971-9	2016	In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation.	GW0742	15-21	peroxisome proliferator activator receptor delta	Mus musculus	144-152
27189971-9	2016	In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation.	GW0742	15-21	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	196-201
27189971-9	2016	In conclusion, GW0742 exerted antihypertensive effects, restoring sympathetic tone and vascular structure and function in AngII-infused mice by PPARbeta activation in brain and vessels inhibiting AngII signaling as a result of RGS5 upregulation.	GW0742	15-21	regulator of G-protein signaling 5	Mus musculus	227-231
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	peroxisome proliferator activator receptor delta	Mus musculus	13-21
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	toll-like receptor 4	Mus musculus	67-70
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	NADPH oxidase 1	Mus musculus	172-176
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	cytochrome b-245, beta polypeptide	Mus musculus	178-182
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	NSFL1 (p97) cofactor (p47)	Mus musculus	184-187
27179975-3	2016	In vivo, the PPARbeta/delta agonist GW0742 treatment prevented the LPS-induced reduction in aortic relaxation, the increase in vascular ROS production, the upregulation of NOX1, NOX2, p47(phox), and p22(phox) mRNA levels, and the endoplasmic reticulum (ER) stress markers in mice.	GW0742	36-42	dynein cytoplasmic 1 heavy chain 1	Mus musculus	199-202
27179975-4	2016	We show that in mouse aortic endothelial cells (MAECs), GW0742 prevented the decreased A23187-stimulated nitric oxide (NO) production, and the increased intracellular ROS levels caused by exposure to LPS in vitro.	GW0742	56-62	toll-like receptor 4	Mus musculus	200-203
27179975-5	2016	The PPARbeta/delta antagonist GSK0660 abolished all these in vivo and in vitro protective effects induced by GW0742.	GW0742	109-115	peroxisome proliferator activator receptor delta	Mus musculus	4-12
27179975-7	2016	The effects of GW0742 on NO and ROS production in MAEC exposed to LPS were abolished by the UCP2 inhibitor genipin or by siRNA targeting UCP-2.	GW0742	15-21	toll-like receptor 4	Mus musculus	66-69
27179975-7	2016	The effects of GW0742 on NO and ROS production in MAEC exposed to LPS were abolished by the UCP2 inhibitor genipin or by siRNA targeting UCP-2.	GW0742	15-21	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	92-96
27179975-7	2016	The effects of GW0742 on NO and ROS production in MAEC exposed to LPS were abolished by the UCP2 inhibitor genipin or by siRNA targeting UCP-2.	GW0742	15-21	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	137-142
26864581-0	2016	PPARdelta agonist GW0742 ameliorates Abeta1-42-induced hippocampal neurotoxicity in mice.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
26864581-3	2016	In the current study, the effect of GW0742, a selective PPARdelta agonist, on Abeta1-42-induced neurotoxicity was investigated in the hippocampus of mice.	GW0742	36-42	peroxisome proliferator activator receptor delta	Mus musculus	56-65
26206209-0	2016	The PPARbeta/delta Agonist GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons: Role of PPARbeta/delta in Neuronal Maturation.	GW0742	27-33	peroxisome proliferator activated receptor delta	Homo sapiens	4-12
26206209-0	2016	The PPARbeta/delta Agonist GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons: Role of PPARbeta/delta in Neuronal Maturation.	GW0742	27-33	peroxisome proliferator activated receptor delta	Homo sapiens	110-118
26206209-4	2016	To get more insight into the molecular mechanism by which PPARbeta/delta may be involved in neuronal maturation processes, in this work a specific PPARbeta/delta agonist, GW0742 was used administered alone or in association with a specific PPARbeta/delta antagonist, the GSK0660, and the parameters involved in neuronal differentiation and maturation were assayed.	GW0742	171-177	peroxisome proliferator activated receptor delta	Homo sapiens	147-155
26206209-4	2016	To get more insight into the molecular mechanism by which PPARbeta/delta may be involved in neuronal maturation processes, in this work a specific PPARbeta/delta agonist, GW0742 was used administered alone or in association with a specific PPARbeta/delta antagonist, the GSK0660, and the parameters involved in neuronal differentiation and maturation were assayed.	GW0742	171-177	peroxisome proliferator activated receptor delta	Homo sapiens	147-155
26997622-3	2016	Balb/c mice were trained on a treadmill and administered both the AMPK activator AICAR and the PPARdelta agonist GW0742 for 4 weeks.	GW0742	113-119	peroxisome proliferator activator receptor delta	Mus musculus	95-104
26997622-7	2016	Citrate synthase activity was elevated in AICAR-treated groups, while PGC-1alpha protein level tended to be increased in GW0742-treated groups.	GW0742	121-127	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	70-80
26686607-3	2016	Here we used computational chemistry methods to investigate the potential for PGI2, beraprost (IP receptor agonist), and GW0742 (PPARbeta/delta agonist), to bind to nuclear receptors, confirmed with pharmacological methods.	GW0742	121-127	peroxisome proliferator-activated receptor delta	Rattus norvegicus	129-137
26768366-3	2016	C2C12 myoblasts treated with a PPARbeta/delta agonist, GW0742 exhibit enhanced myotube formation and muscle-specific gene expression.	GW0742	55-61	peroxisome proliferator activated receptor delta	Homo sapiens	31-39
26768366-4	2016	GW0742 treatment dramatically activates promyogenic kinases, p38MAPK and Akt, in a dose-dependent manner.	GW0742	0-6	AKT serine/threonine kinase 1	Homo sapiens	73-76
26768366-5	2016	GW0742-stimulated myoblast differentiation is mediated by p38MAPK and Akt, since it failed to restore myoblast differentiation repressed by inhibition of p38MAPK and Akt.	GW0742	0-6	AKT serine/threonine kinase 1	Homo sapiens	70-73
26768366-6	2016	In addition, GW0742 treatment enhances MyoD-reporter activities.	GW0742	13-19	myogenic differentiation 1	Homo sapiens	39-43
27150147-0	2016	Pulmonary Administration of GW0742, a High-Affinity Peroxisome Proliferator-Activated Receptor Agonist, Repairs Collapsed Alveoli in an Elastase-Induced Mouse Model of Emphysema.	GW0742	28-34	peroxisome proliferator activated receptor alpha	Mus musculus	52-94
27150147-5	2016	Here, we demonstrate that treatment using a high-affinity PPARbeta/delta agonist, GW0742, reverses the lung tissue damage induced by elastase in emphysema-model mice and improves respiratory function.	GW0742	82-88	peroxisome proliferator activator receptor delta	Mus musculus	58-66
26628385-9	2016	In addition, GW0742, a specific agonist of PPARbeta/delta, was used to treat SAH in rats, the effects of which were evaluated by neurological scoring and Evans blue extravasation.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	43-51
26630504-9	2015	Studies in M3CT3-E1 cells showed that the PPARss agonist GW0742 activated the PPRE-mediated luciferase expression and up-regulated peroxisomal gene transcription (Pex11, Pex13, Pex14, Acox1 and Cat), whereas the PPARss antagonist GSK0660 led to repression of the PPRE and a decrease of the corresponding mRNA levels.	GW0742	57-63	peroxisomal biogenesis factor 13	Mus musculus	170-175
26630504-9	2015	Studies in M3CT3-E1 cells showed that the PPARss agonist GW0742 activated the PPRE-mediated luciferase expression and up-regulated peroxisomal gene transcription (Pex11, Pex13, Pex14, Acox1 and Cat), whereas the PPARss antagonist GSK0660 led to repression of the PPRE and a decrease of the corresponding mRNA levels.	GW0742	57-63	peroxisomal biogenesis factor 14	Mus musculus	177-182
26630504-9	2015	Studies in M3CT3-E1 cells showed that the PPARss agonist GW0742 activated the PPRE-mediated luciferase expression and up-regulated peroxisomal gene transcription (Pex11, Pex13, Pex14, Acox1 and Cat), whereas the PPARss antagonist GSK0660 led to repression of the PPRE and a decrease of the corresponding mRNA levels.	GW0742	57-63	acyl-Coenzyme A oxidase 1, palmitoyl	Mus musculus	184-189
26630504-9	2015	Studies in M3CT3-E1 cells showed that the PPARss agonist GW0742 activated the PPRE-mediated luciferase expression and up-regulated peroxisomal gene transcription (Pex11, Pex13, Pex14, Acox1 and Cat), whereas the PPARss antagonist GSK0660 led to repression of the PPRE and a decrease of the corresponding mRNA levels.	GW0742	57-63	catalase	Mus musculus	194-197
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	thymoma viral proto-oncogene 1	Mus musculus	39-42
26253087-5	2015	The PPARbeta/delta antagonist GSK0660 abolished all of these protective effects induced by GW0742.	GW0742	91-97	peroxisome proliferator activator receptor delta	Mus musculus	4-12
26253087-7	2015	The effects of GW0742 on acetylcholine- induced relaxation in aorta and on NO and ROS production in MAECs exposed to palmitate were abolished by the CPT-1 inhibitor etomoxir or by siRNA targeting CPT-1.	GW0742	15-21	carnitine palmitoyltransferase 1b, muscle	Mus musculus	149-154
26253087-7	2015	The effects of GW0742 on acetylcholine- induced relaxation in aorta and on NO and ROS production in MAECs exposed to palmitate were abolished by the CPT-1 inhibitor etomoxir or by siRNA targeting CPT-1.	GW0742	15-21	carnitine palmitoyltransferase 1b, muscle	Mus musculus	196-201
26253087-8	2015	GW0742 also inhibited the increase in DAG (diacylglycerol), PKCalpha/betaII (protein kinase Calpha/betaII) activation, and phosphorylation of eNOS at Thr495 induced by palmitate in MAECs, which were abolished by etomoxir.	GW0742	0-6	protein kinase C, alpha	Mus musculus	60-75
26508837-14	2015	Western blotting analysis indicated that GW0742 reversed the decrease in GLUT4 and markedly reduced the increased PEPCK in liver.	GW0742	41-47	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	114-119
26508837-15	2015	CONCLUSION: The data showed that GW0742 has the ability to improve glucose homeostasis in diabetic rats through activation of PPAR-delta.	GW0742	33-39	peroxisome proliferator activated receptor alpha	Rattus norvegicus	126-130
26508837-0	2015	Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.	GW0742	28-34	peroxisome proliferator activated receptor alpha	Rattus norvegicus	15-19
26508837-3	2015	GW0742, a selective peroxisome proliferator-activated receptor (PPAR)-delta agonist, has been shown to ameliorate metabolic abnormalities including IR in skeletal muscle in mice fed high-fructose corn syrup.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	20-75
26508837-14	2015	Western blotting analysis indicated that GW0742 reversed the decrease in GLUT4 and markedly reduced the increased PEPCK in liver.	GW0742	41-47	solute carrier family 2 member 4	Rattus norvegicus	73-78
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	nitric oxide synthase 3, endothelial cell	Mus musculus	47-80
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	caveolin 1, caveolae protein	Mus musculus	128-138
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	nitric oxide synthase 3, endothelial cell	Mus musculus	139-172
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	NADPH oxidase 1	Mus musculus	209-214
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	toll-like receptor 4	Mus musculus	216-265
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	interleukin 6	Mus musculus	271-284
26147382-8	2015	Moreover, GW0742 increased both aortic Akt and endothelial nitric oxide synthase phosphorylation, and inhibited the increase in caveolin-1/endothelial nitric oxide synthase interaction, ethidium fluorescence, NOX-1, Toll-like receptor 4, tumor necrosis factor-alpha, and interleukin-6 expression, and IkappaBalpha phosphorylation found in aortae from the HFD group.	GW0742	10-16	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	301-313
25662586-2	2015	In the current study, we determined the effects of the PPAR-beta/delta agonist GW0742 on HDL composition and the expression of liver HDL-related genes in mice and cultured human cells.	GW0742	79-85	peroxisome proliferator activator receptor delta	Mus musculus	55-64
25828396-6	2015	The selective PPARbeta/delta agonist GW0742 inhibited the H2O2-induced apoptosis and increased cell viability.	GW0742	37-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	14-22
25662586-4	2015	GW0742 upregulated liver phospholipid transfer protein (Pltp) gene expression and increased serum PLTP activity in mice.	GW0742	0-6	phospholipid transfer protein	Mus musculus	56-60
25662586-4	2015	GW0742 upregulated liver phospholipid transfer protein (Pltp) gene expression and increased serum PLTP activity in mice.	GW0742	0-6	phospholipid transfer protein	Mus musculus	98-102
25662586-6	2015	The GW0742-mediated effects on liver Pltp expression and serum enzyme activity were completely abolished in PPAR-beta/delta-deficient mice.	GW0742	4-10	phospholipid transfer protein	Mus musculus	37-41
25662586-6	2015	The GW0742-mediated effects on liver Pltp expression and serum enzyme activity were completely abolished in PPAR-beta/delta-deficient mice.	GW0742	4-10	peroxisome proliferator activator receptor delta	Mus musculus	108-117
25662586-7	2015	GW0742 also stimulated PLTP mRNA expression in mouse J774 macrophages, differentiated human THP-1 macrophages and human hepatoma Huh7.	GW0742	0-6	phospholipid transfer protein	Mus musculus	23-27
25662586-7	2015	GW0742 also stimulated PLTP mRNA expression in mouse J774 macrophages, differentiated human THP-1 macrophages and human hepatoma Huh7.	GW0742	0-6	GLI family zinc finger 2	Homo sapiens	92-97
25662586-8	2015	Collectively, our findings demonstrate a common transcriptional upregulation by GW0742-activated PPAR-beta/delta of Pltp expression in cultured cells and in mouse liver resulting in enhanced serum PLTP activity.	GW0742	80-86	peroxisome proliferator activator receptor delta	Mus musculus	97-106
25662586-8	2015	Collectively, our findings demonstrate a common transcriptional upregulation by GW0742-activated PPAR-beta/delta of Pltp expression in cultured cells and in mouse liver resulting in enhanced serum PLTP activity.	GW0742	80-86	phospholipid transfer protein	Mus musculus	116-120
25662586-8	2015	Collectively, our findings demonstrate a common transcriptional upregulation by GW0742-activated PPAR-beta/delta of Pltp expression in cultured cells and in mouse liver resulting in enhanced serum PLTP activity.	GW0742	80-86	phospholipid transfer protein	Mus musculus	197-201
25592770-6	2015	METHODS: 5XFAD mice were orally treated with the PPARdelta agonist GW0742 for 2 weeks.	GW0742	67-73	peroxisome proliferator activator receptor delta	Mus musculus	49-58
25592770-14	2015	CONCLUSIONS: This study demonstrates that GW0742 treatment has a prominent anti-inflammatory effect in 5XFAD mice and suggests that PPARdelta agonists may have therapeutic utility in treating AD.	GW0742	42-48	peroxisome proliferator activator receptor delta	Mus musculus	132-141
25147052-9	2015	Finally, agonists for PPARbeta (GW0742) or PPARgamma (GW1929) increased E-FABP expression and enhanced the resistance of NGFDPC12 cells to PAM-LTx.	GW0742	32-38	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-30
25147052-9	2015	Finally, agonists for PPARbeta (GW0742) or PPARgamma (GW1929) increased E-FABP expression and enhanced the resistance of NGFDPC12 cells to PAM-LTx.	GW0742	32-38	fatty acid binding protein 5	Rattus norvegicus	72-78
25147052-9	2015	Finally, agonists for PPARbeta (GW0742) or PPARgamma (GW1929) increased E-FABP expression and enhanced the resistance of NGFDPC12 cells to PAM-LTx.	GW0742	32-38	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	139-142
24939361-9	2014	Our data reveals a new non-genomic mechanism of GW0742, which ameliorates the generation of reactive oxygen species and attenuates ERK1/2 and PI3K/Akt signaling, with implications in the regulation of cardiac hypertrophic response.	GW0742	48-54	mitogen-activated protein kinase 3	Homo sapiens	131-137
24939361-9	2014	Our data reveals a new non-genomic mechanism of GW0742, which ameliorates the generation of reactive oxygen species and attenuates ERK1/2 and PI3K/Akt signaling, with implications in the regulation of cardiac hypertrophic response.	GW0742	48-54	AKT serine/threonine kinase 1	Homo sapiens	147-150
24939361-0	2014	The PPARbeta/delta agonist GW0742 modulates signaling pathways associated with cardiac myocyte growth via a non-genomic redox mechanism.	GW0742	27-33	peroxisome proliferator activated receptor delta	Homo sapiens	4-12
24939361-5	2014	The selective PPARbeta/delta agonist GW0742 attenuated ERK1/2 and Akt phosphorylation that was stimulated by growth promoting agonists (phenylephrine, insulin or IGF-1).	GW0742	37-43	peroxisome proliferator activated receptor delta	Homo sapiens	14-22
24774438-8	2014	RESULTS: The pretreatment with GW0742 significantly increased the expression of Bcl-2, and significantly decreased in the volume of infarction, NDS, edema, expressions of IL-1beta, NF-kappaB, TNFalpha, and Bax, contents of iNOS and the apoptotic cells in infarct cerebral hemisphere compared with rats in the vehicle group at 24 hours after MCAO.	GW0742	31-37	BCL2, apoptosis regulator	Rattus norvegicus	80-85
24939361-5	2014	The selective PPARbeta/delta agonist GW0742 attenuated ERK1/2 and Akt phosphorylation that was stimulated by growth promoting agonists (phenylephrine, insulin or IGF-1).	GW0742	37-43	mitogen-activated protein kinase 3	Homo sapiens	55-61
24939361-5	2014	The selective PPARbeta/delta agonist GW0742 attenuated ERK1/2 and Akt phosphorylation that was stimulated by growth promoting agonists (phenylephrine, insulin or IGF-1).	GW0742	37-43	AKT serine/threonine kinase 1	Homo sapiens	66-69
24939361-5	2014	The selective PPARbeta/delta agonist GW0742 attenuated ERK1/2 and Akt phosphorylation that was stimulated by growth promoting agonists (phenylephrine, insulin or IGF-1).	GW0742	37-43	insulin	Homo sapiens	151-158
24939361-5	2014	The selective PPARbeta/delta agonist GW0742 attenuated ERK1/2 and Akt phosphorylation that was stimulated by growth promoting agonists (phenylephrine, insulin or IGF-1).	GW0742	37-43	insulin like growth factor 1	Homo sapiens	162-167
24814977-9	2014	Treatment of mouse AML12 hepatocytes with the PPARbeta agonist (GW0742) decreased (14)C-18:2,n-6 in TGs but did not affect beta-oxidation.	GW0742	64-70	peroxisome proliferator activator receptor delta	Mus musculus	46-54
24774438-8	2014	RESULTS: The pretreatment with GW0742 significantly increased the expression of Bcl-2, and significantly decreased in the volume of infarction, NDS, edema, expressions of IL-1beta, NF-kappaB, TNFalpha, and Bax, contents of iNOS and the apoptotic cells in infarct cerebral hemisphere compared with rats in the vehicle group at 24 hours after MCAO.	GW0742	31-37	interleukin 1 beta	Rattus norvegicus	171-179
24774438-8	2014	RESULTS: The pretreatment with GW0742 significantly increased the expression of Bcl-2, and significantly decreased in the volume of infarction, NDS, edema, expressions of IL-1beta, NF-kappaB, TNFalpha, and Bax, contents of iNOS and the apoptotic cells in infarct cerebral hemisphere compared with rats in the vehicle group at 24 hours after MCAO.	GW0742	31-37	tumor necrosis factor	Rattus norvegicus	192-200
24774438-8	2014	RESULTS: The pretreatment with GW0742 significantly increased the expression of Bcl-2, and significantly decreased in the volume of infarction, NDS, edema, expressions of IL-1beta, NF-kappaB, TNFalpha, and Bax, contents of iNOS and the apoptotic cells in infarct cerebral hemisphere compared with rats in the vehicle group at 24 hours after MCAO.	GW0742	31-37	BCL2 associated X, apoptosis regulator	Rattus norvegicus	206-209
24774438-8	2014	RESULTS: The pretreatment with GW0742 significantly increased the expression of Bcl-2, and significantly decreased in the volume of infarction, NDS, edema, expressions of IL-1beta, NF-kappaB, TNFalpha, and Bax, contents of iNOS and the apoptotic cells in infarct cerebral hemisphere compared with rats in the vehicle group at 24 hours after MCAO.	GW0742	31-37	nitric oxide synthase 2	Rattus norvegicus	223-227
24527778-7	2014	The co-incubation with the PPARbeta agonists GW0742 or L165041 prevented all these effects induced by high glucose.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	27-35
24774438-9	2014	CONCLUSIONS: The study suggests the neuroprotective effect of the PPAR-beta/delta ligand GW0742 in acute ischemic stroke by a mechanism that may involve its anti-inflammatory and antiapoptotic action.	GW0742	89-95	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-75
24486703-7	2014	However, activation of the PPARdelta signaling pathway by the agonist GW0742 reversed all these changes induced by Hcy.	GW0742	70-76	peroxisome proliferator activated receptor delta	Homo sapiens	27-36
24635117-2	2014	In this study, we have investigated the effect of GW0742, a PPAR-beta/delta agonist in rat model of cognitive impairment associated with PD.	GW0742	50-56	peroxisome proliferator-activated receptor delta	Rattus norvegicus	60-69
24635117-4	2014	PPAR-beta/delta agonist GW0742 at a dose of 30 and 100 microg/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test.	GW0742	24-30	peroxisome proliferator-activated receptor delta	Rattus norvegicus	0-9
24352213-4	2014	In the HMC, both GW0742, an authentic PPAR-delta agonist, and telmisartan enhanced PPAR response element (PPRE)-luciferase activity dose dependently, and these increases were blunted by GSK0660, a specific PPAR-delta antagonist, but not by GW9662, a PPAR-gamma antagonist.	GW0742	17-23	peroxisome proliferator activated receptor delta	Homo sapiens	38-48
24352213-4	2014	In the HMC, both GW0742, an authentic PPAR-delta agonist, and telmisartan enhanced PPAR response element (PPRE)-luciferase activity dose dependently, and these increases were blunted by GSK0660, a specific PPAR-delta antagonist, but not by GW9662, a PPAR-gamma antagonist.	GW0742	17-23	peroxisome proliferator activated receptor alpha	Homo sapiens	38-42
24352213-4	2014	In the HMC, both GW0742, an authentic PPAR-delta agonist, and telmisartan enhanced PPAR response element (PPRE)-luciferase activity dose dependently, and these increases were blunted by GSK0660, a specific PPAR-delta antagonist, but not by GW9662, a PPAR-gamma antagonist.	GW0742	17-23	peroxisome proliferator activated receptor delta	Homo sapiens	206-216
24352213-4	2014	In the HMC, both GW0742, an authentic PPAR-delta agonist, and telmisartan enhanced PPAR response element (PPRE)-luciferase activity dose dependently, and these increases were blunted by GSK0660, a specific PPAR-delta antagonist, but not by GW9662, a PPAR-gamma antagonist.	GW0742	17-23	peroxisome proliferator activated receptor gamma	Homo sapiens	250-260
24716857-4	2014	FINDINGS: Treatment of MDBK cells with GW0742 caused a strong increase in the mRNA level of the known bovine PPARbeta/delta target gene CPT1A in MDBK cells indicating activation of PPARbeta/delta.	GW0742	39-45	peroxisome proliferator activated receptor delta	Bos taurus	109-117
24716857-4	2014	FINDINGS: Treatment of MDBK cells with GW0742 caused a strong increase in the mRNA level of the known bovine PPARbeta/delta target gene CPT1A in MDBK cells indicating activation of PPARbeta/delta.	GW0742	39-45	carnitine palmitoyltransferase 1A	Bos taurus	136-141
24716857-4	2014	FINDINGS: Treatment of MDBK cells with GW0742 caused a strong increase in the mRNA level of the known bovine PPARbeta/delta target gene CPT1A in MDBK cells indicating activation of PPARbeta/delta.	GW0742	39-45	peroxisome proliferator activated receptor delta	Bos taurus	181-189
24716857-6	2014	In addition, GW0742 increased Na+-dependent carnitine uptake, which is mediated by OCTN2, into MDBK cells, whereas treatment of cells with the PPARbeta/delta antagonist completely abolished the stimulatory effect of GW0742 on carnitine uptake.	GW0742	216-222	peroxisome proliferator activated receptor delta	Bos taurus	143-151
25485183-3	2014	The GW0742 alcohol derivative was more active than the ester in respect to VDR but less active in regard to PPARdelta.	GW0742	4-10	peroxisome proliferator activated receptor delta	Homo sapiens	108-117
24128860-2	2014	SC cultures obtained from 20-day-old rats were incubated with WY14643 or GW0742-pharmacological activators of PPAR alpha and PPAR beta/delta respectively.	GW0742	73-79	peroxisome proliferator activated receptor alpha	Rattus norvegicus	110-120
24128860-2	2014	SC cultures obtained from 20-day-old rats were incubated with WY14643 or GW0742-pharmacological activators of PPAR alpha and PPAR beta/delta respectively.	GW0742	73-79	peroxisome proliferator-activated receptor delta	Rattus norvegicus	125-134
25485183-0	2014	Modulation of Transcription mediated by the Vitamin D Receptor and the Peroxisome Proliferator-Activated Receptor delta in the presence of GW0742 analogs.	GW0742	139-145	vitamin D receptor	Homo sapiens	44-62
25485183-0	2014	Modulation of Transcription mediated by the Vitamin D Receptor and the Peroxisome Proliferator-Activated Receptor delta in the presence of GW0742 analogs.	GW0742	139-145	peroxisome proliferator activated receptor delta	Homo sapiens	71-119
25485183-1	2014	Herein we describe the evaluation of GW0742 analogs in respect to their ability to modulate transcription mediated by the vitamin D receptor (VDR) and the peroxisome proliferator activated receptor (PPAR) delta.	GW0742	37-43	vitamin D receptor	Homo sapiens	122-140
25485183-1	2014	Herein we describe the evaluation of GW0742 analogs in respect to their ability to modulate transcription mediated by the vitamin D receptor (VDR) and the peroxisome proliferator activated receptor (PPAR) delta.	GW0742	37-43	vitamin D receptor	Homo sapiens	142-145
25485183-1	2014	Herein we describe the evaluation of GW0742 analogs in respect to their ability to modulate transcription mediated by the vitamin D receptor (VDR) and the peroxisome proliferator activated receptor (PPAR) delta.	GW0742	37-43	peroxisome proliferator activated receptor alpha	Homo sapiens	155-197
25485183-1	2014	Herein we describe the evaluation of GW0742 analogs in respect to their ability to modulate transcription mediated by the vitamin D receptor (VDR) and the peroxisome proliferator activated receptor (PPAR) delta.	GW0742	37-43	peroxisome proliferator activated receptor alpha	Homo sapiens	199-203
25485183-3	2014	The GW0742 alcohol derivative was more active than the ester in respect to VDR but less active in regard to PPARdelta.	GW0742	4-10	vitamin D receptor	Homo sapiens	75-78
24294133-3	2013	PANC-1 cells cultured in RPMI-1640 were exposed to the commonly used ERK1/2 pathway inhibitor PD98059 and PPAR delta agonist GW0742.	GW0742	125-131	peroxisome proliferator activated receptor delta	Homo sapiens	106-116
23943160-4	2013	We found that when activated with the highly selective PPARbeta/delta agonists, GW0742 and GW501516, PPARbeta/delta inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines.	GW0742	80-86	peroxisome proliferator activated receptor delta	Homo sapiens	55-63
23943160-4	2013	We found that when activated with the highly selective PPARbeta/delta agonists, GW0742 and GW501516, PPARbeta/delta inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines.	GW0742	80-86	peroxisome proliferator activated receptor delta	Homo sapiens	101-109
26266797-1	2013	BACKGROUND: In un-resuscitated rodent models of septic shock, the peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) agonist GW0742 improved visceral organ function.	GW0742	146-152	PPARBETA	Sus scrofa	66-119
26266797-1	2013	BACKGROUND: In un-resuscitated rodent models of septic shock, the peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) agonist GW0742 improved visceral organ function.	GW0742	146-152	PPARBETA	Sus scrofa	121-130
25006409-0	2013	The peroxisome proliferator-activated receptor beta/delta agonist GW0742 has direct protective effects on right heart hypertrophy.	GW0742	66-72	peroxisome proliferator activator receptor delta	Mus musculus	4-51
25006409-15	2013	In conclusion, the PPARbeta/delta agonist GW0742 has direct protective effects on the right heart in vivo.	GW0742	42-48	peroxisome proliferator activator receptor delta	Mus musculus	19-27
24294133-6	2013	It was also found that the increase in the expression of Delta6D in response to GW0742 was significantly inhibited by PD98059 (>40%, P < 0.05) or EGF receptor-selective inhibitor AG1478 (>25%, P < 0.05) pretreatment.	GW0742	80-86	fatty acid desaturase 2	Homo sapiens	57-64
23499837-0	2013	The PPARdelta agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampal-dependent cognitive impairment after whole-brain irradiation.	GW0742	22-28	peroxisome proliferator activator receptor delta	Mus musculus	4-13
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	GW0742	119-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	45-98
23752977-1	2013	AIMS: We analysed the chronic effects of the peroxisome proliferator-activated receptor beta/delta (PPAR-beta) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.	GW0742	119-125	peroxisome proliferator-activated receptor delta	Rattus norvegicus	100-109
23752977-6	2013	GW0742, at 20 mg kg(-1) day(-1), attenuated ET-1 contraction by increasing RGS5 expression and restored the intracellular redox balance by reducing NADPH-oxidase activity, and by increasing the antioxidant genes expression.	GW0742	0-6	endothelin 1	Rattus norvegicus	44-48
23752977-6	2013	GW0742, at 20 mg kg(-1) day(-1), attenuated ET-1 contraction by increasing RGS5 expression and restored the intracellular redox balance by reducing NADPH-oxidase activity, and by increasing the antioxidant genes expression.	GW0742	0-6	regulator of G-protein signaling 5	Rattus norvegicus	75-79
23752977-7	2013	The PPAR-beta antagonist GSK0660 prevented all vascular changes induced by GW0742 but not its antihypertensive effects.	GW0742	75-81	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	62-71
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	endothelin 1	Rattus norvegicus	97-101
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	regulator of G-protein signaling 5	Rattus norvegicus	152-156
23752977-8	2013	CONCLUSION: Vascular protective effects of GW0742 operate via PPAR-beta by interference with the ET-1 signalling as a result of increased expression of RGS5 and up-regulation of antioxidant genes and via PPAR-beta-independent mechanisms to decrease blood pressure.	GW0742	43-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	204-213
23915387-3	2013	OBJECTIVES: In this study, we investigated the effects of GW-0742, a synthetic high-affinity PPAR-beta/delta agonist, on neointimal hyperplasia after arterial injury.	GW0742	58-65	peroxisome proliferator activated receptor delta	Homo sapiens	93-102
23915387-8	2013	GW-0742 significantly suppressed IL-6 protein production, the expression of proliferating cell nuclear antigen in the neointima and enhanced CD31 expression.	GW0742	0-7	interleukin 6	Homo sapiens	33-37
23915387-8	2013	GW-0742 significantly suppressed IL-6 protein production, the expression of proliferating cell nuclear antigen in the neointima and enhanced CD31 expression.	GW0742	0-7	platelet and endothelial cell adhesion molecule 1	Homo sapiens	141-145
23499837-3	2013	In this study, we determined if the peroxisomal proliferator-activated receptor (PPAR) delta agonist GW0742 can prevent radiation-induced brain injury in C57Bl/6 wild-type (WT) and PPARdelta knockout (KO) mice.	GW0742	101-107	peroxisome proliferator activated receptor alpha	Mus musculus	36-79
23499837-3	2013	In this study, we determined if the peroxisomal proliferator-activated receptor (PPAR) delta agonist GW0742 can prevent radiation-induced brain injury in C57Bl/6 wild-type (WT) and PPARdelta knockout (KO) mice.	GW0742	101-107	peroxisome proliferator activated receptor alpha	Mus musculus	81-85
23499837-3	2013	In this study, we determined if the peroxisomal proliferator-activated receptor (PPAR) delta agonist GW0742 can prevent radiation-induced brain injury in C57Bl/6 wild-type (WT) and PPARdelta knockout (KO) mice.	GW0742	101-107	peroxisome proliferator activator receptor delta	Mus musculus	181-190
23499837-4	2013	Dietary GW0742 prevented the acute increase in IL-1beta mRNA and ERK phosphorylation measured at 3h after a single 10-Gy dose of WBI; it also prevented the increase in the number of activated hippocampal microglia 1 week after WBI.	GW0742	8-14	interleukin 1 beta	Mus musculus	47-55
22945906-8	2013	Induction of HO-1 by peroxisome proliferator-activated receptor delta agonist (GW0742) prevented the effect of nicotine.	GW0742	79-85	heme oxygenase 1	Homo sapiens	13-17
23713684-0	2013	Peroxisome proliferation-activated receptor delta agonist GW0742 interacts weakly with multiple nuclear receptors, including the vitamin D receptor.	GW0742	58-64	vitamin D receptor	Homo sapiens	129-147
23713684-3	2013	Peroxisome proliferator-activated receptor (PPAR) delta agonist GW0742 was among the identified VDR-coactivator inhibitors and has been characterized herein as a pan nuclear receptor antagonist at concentrations of > 12.1 muM.	GW0742	64-70	peroxisome proliferator activated receptor alpha	Homo sapiens	0-42
23713684-3	2013	Peroxisome proliferator-activated receptor (PPAR) delta agonist GW0742 was among the identified VDR-coactivator inhibitors and has been characterized herein as a pan nuclear receptor antagonist at concentrations of > 12.1 muM.	GW0742	64-70	peroxisome proliferator activated receptor alpha	Homo sapiens	44-48
23713684-3	2013	Peroxisome proliferator-activated receptor (PPAR) delta agonist GW0742 was among the identified VDR-coactivator inhibitors and has been characterized herein as a pan nuclear receptor antagonist at concentrations of > 12.1 muM.	GW0742	64-70	vitamin D receptor	Homo sapiens	96-99
23713684-4	2013	The highest antagonist activity for GW0742 was found for VDR and the androgen receptor.	GW0742	36-42	vitamin D receptor	Homo sapiens	57-60
23713684-4	2013	The highest antagonist activity for GW0742 was found for VDR and the androgen receptor.	GW0742	36-42	androgen receptor	Homo sapiens	69-86
23713684-5	2013	Surprisingly, GW0742 behaved as a PPAR agonist and antagonist, activating transcription at lower concentrations and inhibiting this effect at higher concentrations.	GW0742	14-20	peroxisome proliferator activated receptor alpha	Homo sapiens	34-38
23713684-10	2013	GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists.	GW0742	0-6	vitamin D receptor	Homo sapiens	20-23
23713684-10	2013	GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists.	GW0742	0-6	vitamin D receptor	Homo sapiens	78-81
23713684-11	2013	Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.	GW0742	94-100	vitamin D receptor	Homo sapiens	18-21
23713684-11	2013	Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.	GW0742	94-100	vitamin D receptor	Homo sapiens	157-160
23716627-2	2013	METHODS: HRMECs were treated with the PPAR-beta/delta agonist GW0742 and the antagonist GSK0660.	GW0742	62-68	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-47
23716627-11	2013	Intravitreal injection of GW0742 significantly increased total retinal Angptl4 protein, but intravitreal injection of GSK0660 had no effect.	GW0742	26-32	angiopoietin-like 4	Rattus norvegicus	71-78
23500098-4	2013	In vitro administration of the PPARdelta antagonist GSK0660 (1 muM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP+) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 muM).	GW0742	213-219	peroxisome proliferator activator receptor delta	Mus musculus	31-40
23724037-4	2013	Thus, we used an agonist of PPARdelta, GW0742, to investigate this issue in the present study.	GW0742	39-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	28-37
23724037-6	2013	In diabetic rats with heart failure, GW0742 at a dose sufficient to activate PPARdelta reversed cardiac contraction without changes in heart rate.	GW0742	37-43	peroxisome proliferator-activated receptor delta	Rattus norvegicus	77-86
23724037-11	2013	CONCLUSION: Activation of PPARdelta by GW0742 increases cardiac contractility but not heart rate.	GW0742	39-45	peroxisome proliferator-activated receptor delta	Rattus norvegicus	26-35
23833373-8	2013	Treatment with ATRA (5 mg/kg/p.o/4 days) and GW0742, a selective PPAR-beta/delta receptor agonist (0.1 mg/kg/i.p/4 days), significantly decreased the paw volume, mechanical and TH as compared to vehicle control.	GW0742	45-51	peroxisome proliferator-activated receptor delta	Rattus norvegicus	65-74
23103566-7	2013	All of the above effects of HFCS-55 were attenuated by the specific PPAR-delta agonist GW0742.	GW0742	87-93	peroxisome proliferator activator receptor delta	Mus musculus	68-78
23103566-8	2013	Thus, we demonstrate for the first time that the specific PPAR-delta agonist GW0742 attenuates the metabolic abnormalities and the renal dysfunction/inflammation caused by chronic HFCS-55 exposure by preventing upregulation of fructokinase (liver) and activation of the NLRP3 inflammasome (kidney).	GW0742	77-83	peroxisome proliferator activator receptor delta	Mus musculus	58-68
23103566-8	2013	Thus, we demonstrate for the first time that the specific PPAR-delta agonist GW0742 attenuates the metabolic abnormalities and the renal dysfunction/inflammation caused by chronic HFCS-55 exposure by preventing upregulation of fructokinase (liver) and activation of the NLRP3 inflammasome (kidney).	GW0742	77-83	NLR family, pyrin domain containing 3	Mus musculus	270-275
22945906-8	2013	Induction of HO-1 by peroxisome proliferator-activated receptor delta agonist (GW0742) prevented the effect of nicotine.	GW0742	79-85	peroxisome proliferator activated receptor delta	Homo sapiens	21-69
23861559-3	2013	This study aimed to investigate the signaling pathways activated in the gastrocnemius muscle by chronic administration of the selective PPAR- delta agonist, GW0742 (1 mg/kg/day for 16 weeks), in male C57Bl6/J mice treated for 30 weeks with high-fructose corn syrup (HFCS), the major sweetener in foods and soft-drinks (15% wt/vol in drinking water).	GW0742	157-163	peroxisome proliferator activator receptor delta	Mus musculus	136-147
23861559-6	2013	GW0742 administration induced PPAR- delta upregulation and improvement in glucose and lipid metabolism.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	30-41
22464549-7	2012	RESULTS: GW0742 significantly increased serum nitrite and VEGFR-2 concentrations and VEGF-to-VEGFR-2 ratio in control and diabetic rats.	GW0742	9-15	kinase insert domain receptor	Rattus norvegicus	58-65
22977012-0	2012	Detection of PPARdelta agonists GW1516 and GW0742 and their metabolites in human urine.	GW0742	43-49	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
22977012-2	2012	To simulate the metabolism of PPARdelta agonist GW0742, in vitro reactions were performed which demonstrated that the main metabolic pathway is oxidation of the acyclic divalent sulfur to give the respective sulfoxide and sulfone.	GW0742	48-54	peroxisome proliferator activated receptor delta	Homo sapiens	30-39
22683600-2	2012	Herein, we have analyzed if the peroxisome proliferator-activated receptor-beta/-delta (PPARbeta/delta) agonist GW0742 exerts protective effects on endothelial function in type 1 diabetic rats.	GW0742	112-118	peroxisome proliferator-activated receptor delta	Rattus norvegicus	32-86
22683600-2	2012	Herein, we have analyzed if the peroxisome proliferator-activated receptor-beta/-delta (PPARbeta/delta) agonist GW0742 exerts protective effects on endothelial function in type 1 diabetic rats.	GW0742	112-118	peroxisome proliferator-activated receptor delta	Rattus norvegicus	88-96
22683600-8	2012	In addition, GW0742 prevented the endothelial dysfunction and the upregulation of prepro endothelin-1 and p47(phox) after the in vitro incubation of aortic rings with high glucose and these effects were prevented by the PPARbeta/delta antagonist GSK0660.	GW0742	13-19	endothelin 1	Rattus norvegicus	89-101
22683600-8	2012	In addition, GW0742 prevented the endothelial dysfunction and the upregulation of prepro endothelin-1 and p47(phox) after the in vitro incubation of aortic rings with high glucose and these effects were prevented by the PPARbeta/delta antagonist GSK0660.	GW0742	13-19	NSFL1 cofactor	Rattus norvegicus	106-109
22683600-8	2012	In addition, GW0742 prevented the endothelial dysfunction and the upregulation of prepro endothelin-1 and p47(phox) after the in vitro incubation of aortic rings with high glucose and these effects were prevented by the PPARbeta/delta antagonist GSK0660.	GW0742	13-19	cytochrome b-245 alpha chain	Rattus norvegicus	110-114
22683600-8	2012	In addition, GW0742 prevented the endothelial dysfunction and the upregulation of prepro endothelin-1 and p47(phox) after the in vitro incubation of aortic rings with high glucose and these effects were prevented by the PPARbeta/delta antagonist GSK0660.	GW0742	13-19	peroxisome proliferator-activated receptor delta	Rattus norvegicus	220-228
22824914-9	2012	In liver tissues, mRNA expressions of TNF-alpha, MCP-1, and PGC-1alpha were significantly decreased in diabetic rats treated with GW0742 compared to diabetic control rats.	GW0742	130-136	tumor necrosis factor	Rattus norvegicus	38-47
22824914-9	2012	In liver tissues, mRNA expressions of TNF-alpha, MCP-1, and PGC-1alpha were significantly decreased in diabetic rats treated with GW0742 compared to diabetic control rats.	GW0742	130-136	C-C motif chemokine ligand 2	Rattus norvegicus	49-54
22824914-9	2012	In liver tissues, mRNA expressions of TNF-alpha, MCP-1, and PGC-1alpha were significantly decreased in diabetic rats treated with GW0742 compared to diabetic control rats.	GW0742	130-136	PPARG coactivator 1 alpha	Rattus norvegicus	60-70
22824914-11	2012	The expression level of Akt and IRS-1 was significantly increased by treatment with GW0742.	GW0742	84-90	AKT serine/threonine kinase 1	Rattus norvegicus	24-27
22824914-11	2012	The expression level of Akt and IRS-1 was significantly increased by treatment with GW0742.	GW0742	84-90	insulin receptor substrate 1	Rattus norvegicus	32-37
22521259-0	2012	Peroxisome proliferator-activated receptor beta/delta agonist GW0742 ameliorates cerulein- and taurocholate-induced acute pancreatitis in mice.	GW0742	62-68	peroxisome proliferator activator receptor delta	Mus musculus	0-47
22464549-7	2012	RESULTS: GW0742 significantly increased serum nitrite and VEGFR-2 concentrations and VEGF-to-VEGFR-2 ratio in control and diabetic rats.	GW0742	9-15	vascular endothelial growth factor A	Rattus norvegicus	58-62
22464549-7	2012	RESULTS: GW0742 significantly increased serum nitrite and VEGFR-2 concentrations and VEGF-to-VEGFR-2 ratio in control and diabetic rats.	GW0742	9-15	kinase insert domain receptor	Rattus norvegicus	93-100
21426320-2	2011	EXPERIMENTAL APPROACH: Human PPARdelta function in lipid metabolism was assessed at baseline, after fasting or when challenged with the GW0742 compound in mice fed a chow diet or high-fat diet (HFD).	GW0742	136-142	peroxisome proliferator activated receptor delta	Homo sapiens	29-38
21685825-0	2012	GW0742, a high-affinity PPAR-delta agonist, mediates protection in an organotypic model of spinal cord damage.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-34
21685825-2	2012	OBJECTIVE: To clarify the protective mechanism of PPAR-delta agonist GW0742 in the injured spinal cord using an in vitro model.	GW0742	69-75	peroxisome proliferator activator receptor delta	Mus musculus	50-60
21685825-10	2012	CONCLUSION: GW0742 reduces the cellular and molecular changes occurring in SCI by targeting different downstream pathways modulating PPAR-delta receptors.	GW0742	12-18	peroxisome proliferator activator receptor delta	Mus musculus	133-143
22606221-4	2012	GW0742 is a synthetic ligand that binds PPARdelta more than 300-fold more tightly than PPARalpha or PPARgamma but the structural basis of PPARdelta:GW0742 interactions and reasons for strong selectivity are not clear.	GW0742	0-6	peroxisome proliferator activated receptor delta	Homo sapiens	40-49
22606221-4	2012	GW0742 is a synthetic ligand that binds PPARdelta more than 300-fold more tightly than PPARalpha or PPARgamma but the structural basis of PPARdelta:GW0742 interactions and reasons for strong selectivity are not clear.	GW0742	0-6	peroxisome proliferator activated receptor delta	Homo sapiens	138-147
22606221-5	2012	Here we report the crystal structure of the PPARdelta:GW0742 complex.	GW0742	54-60	peroxisome proliferator activated receptor delta	Homo sapiens	44-53
22606221-6	2012	Comparisons of the PPARdelta:GW0742 complex with published structures of PPARs in complex with alpha and gamma selective agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play special roles in PPARdelta selective binding and experimental and computational analysis of effects of mutations in these residues confirms this and suggests that bulky substituents that line the PPARalpha and gamma ligand binding pockets as structural barriers for GW0742 binding.	GW0742	29-35	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
22606221-6	2012	Comparisons of the PPARdelta:GW0742 complex with published structures of PPARs in complex with alpha and gamma selective agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play special roles in PPARdelta selective binding and experimental and computational analysis of effects of mutations in these residues confirms this and suggests that bulky substituents that line the PPARalpha and gamma ligand binding pockets as structural barriers for GW0742 binding.	GW0742	29-35	peroxisome proliferator activated receptor delta	Homo sapiens	253-262
22606221-6	2012	Comparisons of the PPARdelta:GW0742 complex with published structures of PPARs in complex with alpha and gamma selective agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play special roles in PPARdelta selective binding and experimental and computational analysis of effects of mutations in these residues confirms this and suggests that bulky substituents that line the PPARalpha and gamma ligand binding pockets as structural barriers for GW0742 binding.	GW0742	29-35	peroxisome proliferator activated receptor alpha	Homo sapiens	432-441
22606221-6	2012	Comparisons of the PPARdelta:GW0742 complex with published structures of PPARs in complex with alpha and gamma selective agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play special roles in PPARdelta selective binding and experimental and computational analysis of effects of mutations in these residues confirms this and suggests that bulky substituents that line the PPARalpha and gamma ligand binding pockets as structural barriers for GW0742 binding.	GW0742	502-508	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
21825230-2	2011	We studied whether the PPARbeta agonist GW0742 might exert antihypertensive effects in spontaneously hypertensive rats (SHRs).	GW0742	40-46	peroxisome proliferator-activated receptor delta	Rattus norvegicus	23-31
21825230-4	2011	GW0742 induced a progressive reduction in systolic arterial blood pressure and heart rate in SHRs and reduced the mesenteric arterial remodeling, the increased aortic vasoconstriction to angiotensin II, and the endothelial dysfunction characteristic of SHRs.	GW0742	0-6	angiotensinogen	Rattus norvegicus	187-201
21825230-6	2011	Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1beta, interleukin 6, or intercellular adhesion molecule 1.	GW0742	10-16	NSFL1 cofactor	Rattus norvegicus	87-90
21825230-6	2011	Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1beta, interleukin 6, or intercellular adhesion molecule 1.	GW0742	10-16	angiotensinogen	Rattus norvegicus	132-146
21825230-6	2011	Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1beta, interleukin 6, or intercellular adhesion molecule 1.	GW0742	10-16	interleukin 1 beta	Rattus norvegicus	315-332
21825230-6	2011	Moreover, GW0742 inhibited vascular superoxide production, downregulated p22(phox) and p47(phox) proteins, decreased both basal and angiotensin II-stimulated NADPH oxidase activity, inhibited extracellular-regulated kinase 1/2 activation, and reduced the expression of the proinflammatory and proatherogenic genes, interleukin 1beta, interleukin 6, or intercellular adhesion molecule 1.	GW0742	10-16	intercellular adhesion molecule 1	Rattus norvegicus	352-385
21426320-5	2011	Plasma metabolic parameters were similar in wild-type and PPARdelta KI mice when fed chow or HFD, and following physiological (fasting) and pharmacological (GW0742 compound) activation of PPARdelta.	GW0742	157-163	peroxisome proliferator activator receptor delta	Mus musculus	188-197
21047550-6	2011	Administration of the selective PPARbeta/delta agonist GW0742 attenuated the renal dysfunction, leukocyte infiltration, and formation of interleukin-6 and tumor necrosis factor-alpha.	GW0742	55-61	peroxisome proliferator-activated receptor delta	Rattus norvegicus	32-40
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	GW0742	91-97	peroxisome proliferator activator receptor delta	Mus musculus	29-76
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	GW0742	91-97	tumor necrosis factor	Mus musculus	190-217
21765606-3	2011	Mice treated with copper and peroxisome proliferator-activated receptor beta/delta agonist GW0742 had significantly less body weight loss, less serum alanine aminotransferase increase, less tumor necrosis factor alpha, macrophage inflammatory protein-2 and 8-hydroxy-2"-deoxyguanosine upregulation than copper treated mice.	GW0742	91-97	chemokine (C-X-C motif) ligand 2	Mus musculus	219-252
21765606-6	2011	Copper also upregulated Fas ligand and Caspase 3/7 activity, effects that were significantly lower in cells also treated with GW0742.	GW0742	126-132	caspase 3	Mus musculus	39-48
21798999-5	2011	We report that PPARbeta activation with GW0742 induces a rapid (2 h) and sustained down-regulation of gamma3-AMPK expression both in mouse skeletal muscles and in culture myotubes.	GW0742	40-46	peroxisome proliferator activator receptor delta	Mus musculus	15-23
21798999-5	2011	We report that PPARbeta activation with GW0742 induces a rapid (2 h) and sustained down-regulation of gamma3-AMPK expression both in mouse skeletal muscles and in culture myotubes.	GW0742	40-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	109-113
21047550-6	2011	Administration of the selective PPARbeta/delta agonist GW0742 attenuated the renal dysfunction, leukocyte infiltration, and formation of interleukin-6 and tumor necrosis factor-alpha.	GW0742	55-61	interleukin 6	Rattus norvegicus	137-182
21047550-8	2011	The beneficial effects of GW0742 were attenuated by the selective PPARbeta/delta antagonist GSK0660.	GW0742	26-32	peroxisome proliferator-activated receptor delta	Rattus norvegicus	66-74
21244753-0	2010	GW0742, a high affinity PPAR-beta/delta agonist reduces lung inflammation induced by bleomycin instillation in mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-33
20709805-4	2010	We demonstrated that administration of GW0742, a specific PPARdelta ligand, provided beneficial effects to rats subjected to cecal ligation and puncture, as shown by reduced systemic release of pro-inflammatory cytokines and neutrophil infiltration in lung, liver, and cecum, when compared with vehicle treatment.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	58-67
20709805-7	2010	Furthermore, in lipopolysaccharide-stimulated J774.A1 macrophages, GW0742 reduced TNFalpha production by inhibiting NF-kappaB activation.	GW0742	67-73	tumor necrosis factor	Mus musculus	82-90
20709805-8	2010	RNA silencing of PPARdelta abrogated the inhibitory effects of GW0742 on TNFalpha production.	GW0742	63-69	peroxisome proliferator activator receptor delta	Mus musculus	17-26
20709805-8	2010	RNA silencing of PPARdelta abrogated the inhibitory effects of GW0742 on TNFalpha production.	GW0742	63-69	tumor necrosis factor	Mus musculus	73-81
20693380-9	2010	All the observed beneficial effects of GW0742 were attenuated by the PPAR-beta/delta antagonist GSK0660.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	69-78
21159610-4	2010	Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	21-29
21159610-4	2010	Ligand activation of PPARbeta/delta with GW0742 caused a PPARbeta/delta-dependent delay in the onset of tumor formation.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	57-65
21244753-5	2010	Therefore, the aim of this study is to investigate the effects of GW0742, a synthetic high affinity PPAR beta/delta agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis.	GW0742	66-72	peroxisome proliferator activator receptor delta	Mus musculus	100-109
20176685-11	2010	30 min before treatment with GW0742) significantly blocked the effect of the PPAR-beta/delta agonist and thus abolished the protective effect.	GW0742	29-35	peroxisome proliferator activator receptor delta	Mus musculus	77-86
20430778-0	2010	GW0742, a selective PPAR-beta/delta agonist, contributes to the resolution of inflammation after gut ischemia/reperfusion injury.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	20-29
20430778-6	2010	This study investigated the effects of GW0742, a potent and selective PPAR-beta/delta agonist, on tissue injury, caused in a mouse model of SAO shock.	GW0742	39-45	peroxisome proliferator activator receptor delta	Mus musculus	70-79
20516370-8	2010	GSK3787 antagonized GW0742-induced expression of Angptl4 in mouse fibroblasts, mouse keratinocytes, and human cancer cell lines.	GW0742	20-26	angiopoietin-like 4	Mus musculus	49-56
19997057-13	2010	Thus, immediate administration of the PPAR-beta/delta ligand GW0742 during reperfusion reduces myocardial infarct size in the rat by a mechanism that may involve inhibition of the activity of glycogen synthase kinase-3beta secondary to activation of the Akt pathway.	GW0742	61-67	peroxisome proliferator-activated receptor delta	Rattus norvegicus	38-47
19997057-13	2010	Thus, immediate administration of the PPAR-beta/delta ligand GW0742 during reperfusion reduces myocardial infarct size in the rat by a mechanism that may involve inhibition of the activity of glycogen synthase kinase-3beta secondary to activation of the Akt pathway.	GW0742	61-67	glycogen synthase kinase 3 beta	Rattus norvegicus	192-222
19997057-13	2010	Thus, immediate administration of the PPAR-beta/delta ligand GW0742 during reperfusion reduces myocardial infarct size in the rat by a mechanism that may involve inhibition of the activity of glycogen synthase kinase-3beta secondary to activation of the Akt pathway.	GW0742	61-67	AKT serine/threonine kinase 1	Rattus norvegicus	254-257
19748995-7	2010	Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice.	GW0742	41-47	peroxisome proliferator activator receptor delta	Mus musculus	249-257
20066433-5	2010	Specific pharmacological activation of PPARbeta using GW0742 or GW501516 in low concentrations inhibits proliferation of human and murine melanoma cells.	GW0742	54-60	peroxisome proliferator activated receptor delta	Homo sapiens	39-47
20407409-0	2010	GW0742, a high-affinity PPAR -beta/delta agonist, inhibits acute lung injury in mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	24-34
20407409-2	2010	The aim of this study was to investigate the effects of a high-affinity PPAR-beta/delta agonist, GW0742, in a mouse model of carrageenan (CAR)-induced pleurisy.	GW0742	97-103	peroxisome proliferator activator receptor delta	Mus musculus	72-81
20407409-7	2010	Thus, based on these findings, we propose that a PPAR-beta/delta agonist such as GW0742 may be useful in the treatment of various inflammatory diseases.	GW0742	81-87	peroxisome proliferator activator receptor delta	Mus musculus	49-58
20209098-0	2010	The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.	GW0742	27-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-12
20209098-6	2010	METHODOLOGY/PRINCIPAL FINDINGS: Here we show that the PPARbeta/delta agonist GW0742 induces vasorelaxation in systemic and pulmonary vessels.	GW0742	77-83	peroxisome proliferator-activated receptor delta	Rattus norvegicus	54-62
20209098-8	2010	In aortic tissue, vascular relaxant effects of GW0742 were not associated with increases in cGMP, cAMP or hyperpolarisation, but were attributed to inhibition of RhoA activity.	GW0742	47-53	ras homolog family member A	Rattus norvegicus	162-166
19660859-4	2010	Inhibition of C20 cell proliferation and clonogenicity was observed following treatment with GW0742 or GW501516, two highly specific PPARbeta/delta ligands.	GW0742	93-99	peroxisome proliferator-activated receptor delta	Rattus norvegicus	133-141
20167109-11	2010	The PPAR-beta/delta agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction syndrome caused by zymosan.	GW0742	29-35	peroxisome proliferator activator receptor delta	Mus musculus	4-13
19906781-9	2010	In human umbilical vein endothelial cells, L-165041 and GW0742 increased nitric oxide (NO) production and Akt and endothelial NOS (eNOS) phosphorylation, which were sensitive to PI3K inhibition and PPAR-beta blockade.	GW0742	56-62	AKT serine/threonine kinase 1	Homo sapiens	106-109
19906781-9	2010	In human umbilical vein endothelial cells, L-165041 and GW0742 increased nitric oxide (NO) production and Akt and endothelial NOS (eNOS) phosphorylation, which were sensitive to PI3K inhibition and PPAR-beta blockade.	GW0742	56-62	nitric oxide synthase 3	Homo sapiens	114-129
19906781-9	2010	In human umbilical vein endothelial cells, L-165041 and GW0742 increased nitric oxide (NO) production and Akt and endothelial NOS (eNOS) phosphorylation, which were sensitive to PI3K inhibition and PPAR-beta blockade.	GW0742	56-62	peroxisome proliferator activated receptor delta	Homo sapiens	198-207
20001953-4	2010	We show that effects of GW0742 are mediated through PPARdelta since no amelioration of EAE clinical scores was observed in PPARdelta-null mice.	GW0742	24-30	peroxisome proliferator activator receptor delta	Mus musculus	52-61
20169010-3	2009	PPARdelta agonist GW0742 (10 mg/kg per day) did not change 3H-tracer plasma appearance, but increased fecal 3H-free sterols excretion by 103% ( p < 0.005) over 48 hours.	GW0742	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
19577614-4	2009	Cell culture experiments revealed that CACT mRNA abundance was higher in liver cells treated with either WY-14,643 or PPARdelta agonist GW0742, but not with PPARgamma agonist troglitazone (TGZ) than in control cells (P<0.05).	GW0742	136-142	solute carrier family 25 (mitochondrial carnitine/acylcarnitine translocase), member 20	Mus musculus	39-43
19577614-4	2009	Cell culture experiments revealed that CACT mRNA abundance was higher in liver cells treated with either WY-14,643 or PPARdelta agonist GW0742, but not with PPARgamma agonist troglitazone (TGZ) than in control cells (P<0.05).	GW0742	136-142	peroxisome proliferator activator receptor delta	Mus musculus	118-127
20169010-4	2009	Total free cholesterol efflux from macrophages to serum (collected from both control and GW0742 groups) was not different, although ABCA1-mediated efflux was significantly higher with GW0742.	GW0742	184-190	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	132-137
18687807-9	2008	Although inhibition of keratinocyte proliferation by GW0742 was PPARbeta/delta-dependent, inhibition of cell proliferation by RA occurred in both genotypes.	GW0742	53-59	peroxisome proliferator activated receptor delta	Homo sapiens	64-72
18593727-0	2008	PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.	GW0742	115-121	peroxisome proliferator activated receptor alpha	Mus musculus	0-10
18593727-0	2008	PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.	GW0742	115-121	peroxisome proliferator activator receptor delta	Mus musculus	22-32
18593727-0	2008	PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.	GW0742	115-121	peroxisome proliferator activated receptor alpha	Mus musculus	0-4
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	glutamic pyruvic transaminase, soluble	Mus musculus	43-46
18622687-0	2008	Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742.	GW0742	123-129	toll-like receptor 4	Mus musculus	14-17
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	tumor necrosis factor	Mus musculus	100-109
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	S100 calcium binding protein A6 (calcyclin)	Mus musculus	111-117
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	chemokine (C-C motif) ligand 2	Mus musculus	119-153
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	chemokine (C-C motif) ligand 2	Mus musculus	155-159
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	tumor necrosis factor receptor superfamily, member 12a	Mus musculus	166-172
18622026-5	2008	GW0742 treatment resulted in reduced serum ALT concentration and lower expression of CCl(4)-induced TNF-alpha, S100A6, monocyte chemoattractant protein-1 (MCP1), and TWEAKr in wild-type mice, and these effects were not observed in PPARbeta/delta-null mice.	GW0742	0-6	peroxisome proliferator activator receptor delta	Mus musculus	231-239
18627005-5	2008	GW0742 and PPARdelta overexpression in hepatocytes induced the expression of insulin-induced gene-1 (Insig-1), an endoplasmic reticulum protein braking SREBP activation, at both the mRNA and the protein levels.	GW0742	0-6	insulin induced gene 1	Mus musculus	77-99
18627005-5	2008	GW0742 and PPARdelta overexpression in hepatocytes induced the expression of insulin-induced gene-1 (Insig-1), an endoplasmic reticulum protein braking SREBP activation, at both the mRNA and the protein levels.	GW0742	0-6	insulin induced gene 1	Mus musculus	101-108
18627005-9	2008	Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1.	GW0742	69-75	insulin induced gene 1	Mus musculus	24-31
18627005-9	2008	Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1.	GW0742	69-75	sterol regulatory element binding transcription factor 1	Mus musculus	79-86
18627005-9	2008	Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1.	GW0742	69-75	peroxisome proliferator activator receptor delta	Mus musculus	120-129
18627005-9	2008	Knockdown of endogenous Insig-1 attenuated the suppressive effect of GW0742 on SREBP-1 and its target genes, indicating PPARdelta inhibited SREBP-1 activation via induction of Insig-1.	GW0742	69-75	sterol regulatory element binding transcription factor 1	Mus musculus	140-147
18622687-0	2008	Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742.	GW0742	123-129	peroxisome proliferator activator receptor delta	Mus musculus	101-109
18622687-1	2008	OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation.	GW0742	127-133	peroxisome proliferator activator receptor delta	Mus musculus	54-62
18622687-1	2008	OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation.	GW0742	127-133	peroxisome proliferator activator receptor delta	Mus musculus	104-112
18622687-1	2008	OBJECTIVE: To define the anti-inflammatory effects of PPARbeta/delta activation by use of the selective PPARbeta/delta ligand (GW0742) in a model of lipopolysaccharide (LPS)-induced pulmonary inflammation.	GW0742	127-133	toll-like receptor 4	Mus musculus	169-172
18622687-2	2008	METHODS: Male BALB/c mice were pretreated for three days with the PPARbeta/delta agonist, GW0742, prior to induction of LPS-mediated pulmonary inflammation.	GW0742	90-96	peroxisome proliferator activator receptor delta	Mus musculus	66-74
18622687-6	2008	Protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in BALF were found to be significantly decreased in GW0742-treated animals (30 mg/kg).	GW0742	138-144	interleukin 6	Mus musculus	58-62
18622687-6	2008	Protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in BALF were found to be significantly decreased in GW0742-treated animals (30 mg/kg).	GW0742	138-144	interleukin 1 beta	Mus musculus	64-72
18622687-6	2008	Protein and mRNA levels of the pro-inflammatory cytokines IL-6, IL-1beta and TNFalpha in BALF were found to be significantly decreased in GW0742-treated animals (30 mg/kg).	GW0742	138-144	tumor necrosis factor	Mus musculus	77-85
18622687-7	2008	A significant decrease in granulocyte macrophage-colony stimulating factor (GM-CSF), a major regulator of neutrophil chemotaxis (via its downstream actions on TNFalpha and other cytokines/chemokines), activation and survival, was also noted in the BALF levels of GW0742-treated animals.	GW0742	263-269	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	26-74
18622687-7	2008	A significant decrease in granulocyte macrophage-colony stimulating factor (GM-CSF), a major regulator of neutrophil chemotaxis (via its downstream actions on TNFalpha and other cytokines/chemokines), activation and survival, was also noted in the BALF levels of GW0742-treated animals.	GW0742	263-269	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	76-82
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	peroxisome proliferator activated receptor delta	Homo sapiens	37-46
18287212-7	2008	The enhanced cardiac expression of interleukin (IL)-6, IL-8, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 induced by I/R were significantly attenuated by GW0742.	GW0742	183-189	interleukin 6	Rattus norvegicus	35-53
18287212-7	2008	The enhanced cardiac expression of interleukin (IL)-6, IL-8, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 induced by I/R were significantly attenuated by GW0742.	GW0742	183-189	intercellular adhesion molecule 1	Rattus norvegicus	61-94
18287212-7	2008	The enhanced cardiac expression of interleukin (IL)-6, IL-8, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 induced by I/R were significantly attenuated by GW0742.	GW0742	183-189	C-C motif chemokine ligand 2	Rattus norvegicus	100-134
18287212-8	2008	Treatment with GW0742 also reduced apoptotic cardiomyocytes by 34% and cardiac caspase-3 activity by 61% (both p < 0.01 versus vehicle).	GW0742	15-21	caspase 3	Rattus norvegicus	79-88
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	angiotensinogen	Homo sapiens	103-108
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	BCL6 transcription repressor	Homo sapiens	206-211
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	regulator of G protein signaling 4	Homo sapiens	213-217
18337495-4	2008	In this model, administration of the PPARdelta agonist GW0742 (1 or 10 mg/kg) substantially attenuated AngII-accelerated atherosclerosis without altering blood pressure and increased vascular expression of Bcl-6, RGS4, and RGS5, which was associated with suppression of inflammatory and atherogenic gene expression in the artery.	GW0742	55-61	regulator of G protein signaling 5	Homo sapiens	223-227
16618765-3	2006	This hypothesis was examined by treating wild-type (Pparb+/+) and Pparb-/- with azoxymethane, coupled with a highly specific PPARbeta ligand, GW0742.	GW0742	142-148	peroxisome proliferator activator receptor delta	Mus musculus	125-133
18048767-6	2008	Chromatin immunoprecipitation assays showed that GW0742 switched the association of BCL-6, a transcription repressor, from PPAR-delta to the vascular cell adhesion molecule (VCAM)-1 promoter.	GW0742	49-55	BCL6 transcription repressor	Homo sapiens	84-89
18048767-6	2008	Chromatin immunoprecipitation assays showed that GW0742 switched the association of BCL-6, a transcription repressor, from PPAR-delta to the vascular cell adhesion molecule (VCAM)-1 promoter.	GW0742	49-55	peroxisome proliferator activated receptor delta	Homo sapiens	123-133
18048767-6	2008	Chromatin immunoprecipitation assays showed that GW0742 switched the association of BCL-6, a transcription repressor, from PPAR-delta to the vascular cell adhesion molecule (VCAM)-1 promoter.	GW0742	49-55	vascular cell adhesion molecule 1	Homo sapiens	141-181
18293166-5	2008	For the examination of PPAR beta/delta effect, the cultured rat cardiac myocytes were pretreated with GW0742 (10 micromol.L(-1)), an agonist of PPARbeta/delta, for 48h before Ang II stimulation.	GW0742	102-108	peroxisome proliferator-activated receptor delta	Rattus norvegicus	144-152
18293166-7	2008	Meanwhile, GW0742 pretreatment exerted inhibition on mRNA expression augmentation of such cytokines as MMP9, MMP2, and IL-1beta in hypertrophic myocytes.	GW0742	11-17	matrix metallopeptidase 9	Rattus norvegicus	103-107
18293166-7	2008	Meanwhile, GW0742 pretreatment exerted inhibition on mRNA expression augmentation of such cytokines as MMP9, MMP2, and IL-1beta in hypertrophic myocytes.	GW0742	11-17	matrix metallopeptidase 2	Rattus norvegicus	109-113
18293166-7	2008	Meanwhile, GW0742 pretreatment exerted inhibition on mRNA expression augmentation of such cytokines as MMP9, MMP2, and IL-1beta in hypertrophic myocytes.	GW0742	11-17	interleukin 1 beta	Rattus norvegicus	119-127
18293166-9	2008	We demonstrate for the first time that GW0742 exerts a beneficial effect on Ang II-induced cardiac hypertrophy and the relation to inflammation response.	GW0742	39-45	angiogenin	Rattus norvegicus	76-79
18054822-5	2008	Culturing cells in the presence of either GW0742 or GW501516 caused upregulation of the known PPARbeta/delta target gene angiopoietin-like protein 4 (ANGPTL4).	GW0742	42-48	peroxisome proliferator activated receptor delta	Homo sapiens	94-102
18054822-5	2008	Culturing cells in the presence of either GW0742 or GW501516 caused upregulation of the known PPARbeta/delta target gene angiopoietin-like protein 4 (ANGPTL4).	GW0742	42-48	angiopoietin like 4	Homo sapiens	150-157
17893232-6	2008	Inhibition of COX2 by nimesulide attenuated colon cancer and ligand activation of PPARbeta/delta by GW0742 had inhibitory effects.	GW0742	100-106	peroxisome proliferator activator receptor delta	Mus musculus	82-90
17254750-5	2007	Ligand activation of PPARbeta/delta with GW0742 prevented cell cycle progression from G1 to S phase and attenuated cell proliferation in N/TERT-1 cells.	GW0742	41-47	peroxisome proliferator activated receptor delta	Homo sapiens	21-29
17254750-5	2007	Ligand activation of PPARbeta/delta with GW0742 prevented cell cycle progression from G1 to S phase and attenuated cell proliferation in N/TERT-1 cells.	GW0742	41-47	telomerase reverse transcriptase	Homo sapiens	139-143
18003597-4	2008	Ethanol (20 mM) reduced the potency of the PPARbeta ligand GW0742, evident by a rightward shift in the GW0742 dose-response curve, whereas for PPARalpha activation by GW7647, ethanol mediated its effects primarily through reducing efficacy as evidenced by a reduction in maximal response.	GW0742	59-65	peroxisome proliferator activated receptor delta	Homo sapiens	43-51
18003597-4	2008	Ethanol (20 mM) reduced the potency of the PPARbeta ligand GW0742, evident by a rightward shift in the GW0742 dose-response curve, whereas for PPARalpha activation by GW7647, ethanol mediated its effects primarily through reducing efficacy as evidenced by a reduction in maximal response.	GW0742	103-109	peroxisome proliferator activated receptor delta	Homo sapiens	43-51
17631136-9	2007	In contrast to the beneficial effect of fenofibrate, the PPARdelta ligand GW0742 accelerated the onset of colitis in IL-10(-/-) mice.	GW0742	74-80	peroxisome proliferator activator receptor delta	Mus musculus	57-66
17631136-9	2007	In contrast to the beneficial effect of fenofibrate, the PPARdelta ligand GW0742 accelerated the onset of colitis in IL-10(-/-) mice.	GW0742	74-80	interleukin 10	Mus musculus	117-122
16698033-5	2006	In this study, we investigated the effects of PPARdelta and its synthetic ligand GW0742 on TNFalpha production in cultured cardiomyocytes.	GW0742	81-87	tumor necrosis factor	Homo sapiens	91-99
16239641-6	2006	The effects of treprostinil sodium on human lung cell proliferation are mimicked by those of the highly selective PPARbeta ligand GW0742.	GW0742	130-136	peroxisome proliferator activated receptor delta	Homo sapiens	114-122
16021179-2	2006	By using of a highly specific ligand (GW0742) and the PPARbeta-null mouse model, activation of PPARbeta was found to selectively induce keratinocyte terminal differentiation and inhibit keratinocyte proliferation.	GW0742	38-44	peroxisome proliferator activator receptor delta	Mus musculus	95-103
16021179-3	2006	Additionally, GW0742 was found to be anti-inflammatory due to inhibition of myeloperoxidase activity, independent of PPARbeta.	GW0742	14-20	myeloperoxidase	Mus musculus	76-91